Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2022 Jul 14;19(7):e1004039. doi: 10.1371/journal.pmed.1004039

Associations between moderate alcohol consumption, brain iron, and cognition in UK Biobank participants: Observational and mendelian randomization analyses

Anya Topiwala 1,*, Chaoyue Wang 2, Klaus P Ebmeier 3, Stephen Burgess 4,5, Steven Bell 6, Daniel F Levey 7,8, Hang Zhou 7,8, Celeste McCracken 9, Adriana Roca-Fernández 10, Steffen E Petersen 11,12,13,14, Betty Raman 9, Masud Husain 2,15,16,17, Joel Gelernter 7,8, Karla L Miller 2, Stephen M Smith 2, Thomas E Nichols 1,2
Editor: Perminder Singh Sachdev18
PMCID: PMC9282660  PMID: 35834561

Abstract

Background

Brain iron deposition has been linked to several neurodegenerative conditions and reported in alcohol dependence. Whether iron accumulation occurs in moderate drinkers is unknown. Our objectives were to investigate evidence in support of causal relationships between alcohol consumption and brain iron levels and to examine whether higher brain iron represents a potential pathway to alcohol-related cognitive deficits.

Methods and findings

Observational associations between brain iron markers and alcohol consumption (n = 20,729 UK Biobank participants) were compared with associations with genetically predicted alcohol intake and alcohol use disorder from 2-sample mendelian randomization (MR). Alcohol intake was self-reported via a touchscreen questionnaire at baseline (2006 to 2010). Participants with complete data were included. Multiorgan susceptibility-weighted magnetic resonance imaging (9.60 ± 1.10 years after baseline) was used to ascertain iron content of each brain region (quantitative susceptibility mapping (QSM) and T2*) and liver tissues (T2*), a marker of systemic iron. Main outcomes were susceptibility (χ) and T2*, measures used as indices of iron deposition. Brain regions of interest included putamen, caudate, hippocampi, thalami, and substantia nigra. Potential pathways to alcohol-related iron brain accumulation through elevated systemic iron stores (liver) were explored in causal mediation analysis. Cognition was assessed at the scan and in online follow-up (5.82 ± 0.86 years after baseline). Executive function was assessed with the trail-making test, fluid intelligence with puzzle tasks, and reaction time by a task based on the “Snap” card game.

Mean age was 54.8 ± 7.4 years and 48.6% were female. Weekly alcohol consumption was 17.7 ± 15.9 units and never drinkers comprised 2.7% of the sample. Alcohol consumption was associated with markers of higher iron (χ) in putamen (β = 0.08 standard deviation (SD) [95% confidence interval (CI) 0.06 to 0.09], p < 0.001), caudate (β = 0.05 [0.04 to 0.07], p < 0.001), and substantia nigra (β = 0.03 [0.02 to 0.05], p < 0.001) and lower iron in the thalami (β = −0.06 [−0.07 to −0.04], p < 0.001). Quintile-based analyses found these associations in those consuming >7 units (56 g) alcohol weekly. MR analyses provided weak evidence these relationships are causal. Genetically predicted alcoholic drinks weekly positively associated with putamen and hippocampus susceptibility; however, these associations did not survive multiple testing corrections. Weak evidence for a causal relationship between genetically predicted alcohol use disorder and higher putamen susceptibility was observed; however, this was not robust to multiple comparisons correction. Genetically predicted alcohol use disorder was associated with serum iron and transferrin saturation. Elevated liver iron was observed at just >11 units (88 g) alcohol weekly c.f. <7 units (56 g). Systemic iron levels partially mediated associations of alcohol intake with brain iron. Markers of higher basal ganglia iron associated with slower executive function, lower fluid intelligence, and slower reaction times. The main limitations of the study include that χ and T2* can reflect changes in myelin as well as iron, alcohol use was self-reported, and MR estimates can be influenced by genetic pleiotropy.

Conclusions

To the best of our knowledge, this study represents the largest investigation of moderate alcohol consumption and iron homeostasis to date. Alcohol consumption above 7 units weekly associated with higher brain iron. Iron accumulation represents a potential mechanism for alcohol-related cognitive decline.


Anya Topiwala and colleagues investigate the observational and genetic associations of alcohol intake with measures of iron levels in the brain and liver, and cognitive function among UK Biobank participants.

Author summary

Why was this study done

  • There is growing evidence that even moderate alcohol consumption negatively impacts the brain, but the mechanisms underlying this are unclear.

  • One possibility is that accumulation of iron in the brain could contribute, as higher brain iron has been described in numerous neurodegenerative conditions including Alzheimer’s and Parkinson’s disease.

  • To the best of our knowledge, there have been no studies investigating if brain iron levels differ by level of alcohol consumption.

What did the researchers do and find

  • In 20,965 participants in a United Kingdom cohort study, we explored relationships between self-reported alcohol consumption and brain iron levels, measured using magnetic resonance imaging.

  • We assessed the association of alcohol intake with blood and liver iron and cognitive measures associated with higher brain iron.

  • Alcohol consumption above 7 units (56 g) weekly was associated with markers of higher iron in the basal ganglia, which in turn associated with worse cognitive function.

  • These observational findings were further supported by analyses using genetic variants as proxies for alcohol consumption.

What do these findings mean

  • These findings suggest that moderate alcohol consumption is associated with higher iron levels in the brain.

  • Brain iron accumulation represents a potential mechanism for alcohol-related cognitive decline.

  • Key limitations are that changes in myelin may also alter imaging markers and alcohol intake was self-reported. It is unclear how our findings generalize to other populations, particularly those which are more ethnically diverse and socioeconomically deprived.

Introduction

There is growing evidence that moderate alcohol consumption adversely impacts brain health, contradicting earlier claims [1,2]. Given the high prevalence of moderate drinking, even small causal associations have substantial population impact [3]. Clarity about the pathological mechanisms by which alcohol acts upon the brain is vital not just for disease aetiology, but also to offer opportunities for intervention.

One largely neglected possibility is that iron overload contributes to alcohol-related neurodegeneration [4,5]. While neurological sequelae of inherited iron overload disorders have long been recognised [6], higher brain iron has now been implicated in the pathophysiology of Alzheimer’s and Parkinson’s diseases [7,8]. Intriguingly, not only does the clinical profile of alcohol-related dementia overlap with these disorders, but also recent observational evidence suggests heavy alcohol use may associate with iron accumulation in the brain [9,10].

What has not previously been explored is whether brain iron accumulation is observed with moderate alcohol consumption, and if so, whether these associations are causal. Furthermore, the mechanisms by which alcohol could influence brain iron and whether there are clinical consequences of subtle elevations in brain iron are unknown. Low levels of drinking have been observationally associated with blood markers of iron homeostasis. However, studies to date have been small, have neglected genetic contributions to iron accumulation (polymorphisms predicting serum iron are highly prevalent in European populations [11]), and serum markers may be poorly specific for body iron stores [1214]. Better insights require well-powered samples with genetic data and concurrent measurement of iron accumulation in brain and liver, the most reliable indicator of the body’s iron stores [15,16]. If iron deposition is mechanistically involved in alcohol’s effect on the brain, there are potential opportunities for earlier monitoring via serum iron markers, as well as intervention with chelating agents [17,18].

In this study, to the best of our knowledge, we performed the largest multiorgan investigation into alcohol-related iron homeostasis to date. Alcohol consumption weekly was divided into quintiles, and never and previous drinkers distinguished. Conventional observational and genetic analyses were triangulated to investigate causal effects (Fig 1). Our objective was to characterise the dose–response relationship of alcohol consumption and brain iron, in observational and mendelian randomization (MR) frameworks. MR is a method that, under specific assumptions, seeks to estimate causal effects. Furthermore, we sought to investigate whether alcohol influences brain iron via changes in systemic iron levels. Lastly, we explored whether higher brain iron represents a potential pathway to alcohol-related cognitive deficits.

Fig 1. Hypothesised model and analysis approach.

Fig 1

(A) and (B) represent unmeasured confounding. Brain iron is measured using T2* and susceptibility (UKB), and body iron stores proxied using liver T2* (UKB). UKB, UK Biobank.

Methods

Participants

Participants were scanned as part of the UK Biobank (UKB) study [19], which recruited volunteers aged 40 to 69 years in 2006 to 2010. Invitations for imaging were sent to all participants. Interested individuals then underwent screening to assess if they were safe and able to tolerate imaging. To date, approximately 50,000 participants have brain scans analysed and approximately 15,000 have abdominal imaging. UKB received ethical approval from the Research Ethics Committee (reference 11/NW/0382), and all participants provided written informed consent. All participants with complete data were included (S1 Fig). No exclusions were made on the basis of dementia diagnosis as no participants with complete data had dementia at the time of imaging. As our study was conducted using existing resources to test an a priori hypothesis, we did not publish a prespecified analysis plan before conducting analyses between November 2021 and January 2022. Further analyses were subsequently performed in March 2022 in response to peer review where highlighted. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline, including guidelines specific for MR studies (S1 and S2 Checklists).

Alcohol consumption

Alcohol intake was self-reported at study baseline through a touchscreen questionnaire. Participants identified themselves as either current, never, or previous drinkers. All groups were included if they had complete data on alcohol intake. For current drinkers, total weekly number of United Kingdom units (1 unit = approximately 8 g; a United States standard drink is 14 g) of alcohol consumed was calculated by summing across beverage types as previously described [20]. To directly compare associations with brain iron at different levels of alcohol intakes, weekly consumption was categorized into quintiles (and octiles for a sensitivity analysis) in current drinkers. The lowest quintile of drinkers was used as the reference category to avoid underestimating alcohol-related risks [21].

Brain imaging

Participants underwent brain MRI at 3 imaging centres (Newcastle upon Tyne, Stockport, or Reading) with identical Siemens Skyra 3T scanners (software VD13) using a standard 32-channel head coil (release date 02.02.2021). Susceptibility-weighted MRI (swMRI) data were used for this study (3D GRE, TE1/TE2/TR = 9.4/20/27 ms, voxel size = 0.8 × 0.8 × 2.0 mm) as a measure sensitive to magnetic tissue constituents. Detailed image preprocessing and quality control pipelines are described elsewhere [22]. Brain iron content was ascertained using quantitative susceptibility mapping (QSM) and T2*, both derived from swMRI data. T2* reflects differences in tissue microstructure related to iron (sequestered to ferritin) and myelin and correlates with postmortem estimates of iron deposits in brain grey matter [23]. Susceptibility reflects the net (sequestered and non-sequestered) content of susceptibility-shifting sources like iron and myelin. Two distinct and complementary metrics of brain iron deposition were used, T2* and QSM, to produce image-derived phenotypes (IDPs). While these metrics are coupled, consistent findings across the 2 will provide greater evidence that iron levels are affected. Subject-specific masks for 14 subcortical regions were derived from the T1-weighted structural brain scan. We then calculated IDPs corresponding to the median T2* and χ values for each region. The 14 regions correspond to left and right of the 7 subcortical structure regions of interest obtained from the T1 image: putamen, caudate, hippocampus, amygdala, pallidum, thalamus, and accumbens. Two additional IDPs were calculated from QSM (left and right substantia nigra) that were not available for T2*. In brief, T2* values were calculated from magnitude data. T2*-induced signal decay was calculated from the 2 echo times. T2* images were spatially filtered to reduce noise and transformed into the T1 space (by linear registration). QSM depends on phase images, which were obtained from individual coil channels, combined, masked, and unwrapped. Magnetic susceptibility (χ) was calculated using a QSM pipeline including background field removal, dipole inversion, and CSF referencing as described elsewhere [10]. Median χ values (in parts per billion) across voxels within each region were calculated, resulting in 16 QSM IDPs.

Liver imaging

Systemic iron levels were estimated using MRI-derived liver iron (a marker of liver iron levels [24]). During the same visit that brain imaging was performed, participants also underwent abdominal imaging on a Siemens 1.5T Magnetom Aera [25]. The acquisition used the LiverMultiScan protocol from Perspectum Diagnostics (thus the data for liver MRI indices is available for a fewer number of participants than brain MRI measures to date). A multi-echo spoiled gradient-echo single breath hold MRI sequence was acquired as a single transverse slice through the centre of the liver. Three ROI, representative of the liver parenchyma, were selected and mean T2* calculated. Iron levels were converted to mg/g. One IDP is liver fat, indexed using proton density fat fraction (PDFF, %), validated against MR spectroscopy and liver biopsy, and has a high specificity and sensitivity for non-alcoholic fatty liver disease [26,27]. The other IDP, corrected T1 (cT1, milliseconds) was used as a marker of inflammation and fibrosis [28]. The data for liver MRI indices are available for a fewer number of participants than brain MRI measures to date.

Genetic variants

Genetic instruments for alcohol, susceptibility, and serum iron markers were selected based on the sentinel variants at genome-wide significant loci (p < 5 × 10−8) reported in the largest publicly available European ancestry genome-wide association studies (GWAS) (S1 Table). The distinct genetic architecture between different alcohol use traits motivates their separate analysis. Genetically predicted alcohol consumption was instrumented using 91/92 (depending on single nucleotide polymorphism (SNP) or suitable proxy availability in outcome data) independent SNPs. These variants were associated with alcohol consumption (log-transformed drinks per week) in the largest published GWAS comprising 941,280 individuals (GWAS and Sequencing Consortium of Alcohol and Nicotine) [29]. Genetic associations were used from the sample excluding UKB to avoid bias towards the observational estimate for overlapping samples [30]. Alcohol use disorder (AUD) was instrumented using 24 conditionally independent genome-wide significant genetic variants in the largest published GWAS comprising the Million Veterans Program and the Psychiatric Genomics Consortium [31]. AUD cases were defined using ICD 9/10 codes within the MVP (n = 45,995) and DSM-IV within the PGC (n = 11,569). Genetic associations with serum markers of iron homeostasis (serum iron, ferritin, transferrin saturation (of iron-binding sites of transferrin occupied by iron), and total iron-binding capacity) were obtained from the largest published GWAS to date (meta-analysis of deCODE, INTERVAL, and Danish Blood Donor Study) [32]. Genetic associations with brain T2* and susceptibility (IV-outcomes) were obtained from the largest GWAS of brain imaging phenotypes [10,33]. All genetic associations were based on GWAS of European ancestry samples. A summary of cohorts comprising the relevant GWAS is given in S1 Table. All publicly available deidentified summary data used have ethical permissions from their respective institutional review boards.

Clinical measures

We utilized the expanded cognitive battery performed on the subset of participants who underwent imaging, which included: trail-making tests (TMTs) (durations, reflecting executive function; numerical–“TMT A;” alphanumeric–“TMT B”), prospective memory (incorrect or correct on first/second attempt on a shape task on screen), and fluid intelligence (sum of correct answers on questions designed to assess logic and reasoning) [34]. A larger subset of the wider UKB study (approximately 100 k) was invited by email to undertake further web-based questionnaires at online follow up (mean 5.82 ± 0.86 years after study baseline). These included: TMT, fluid intelligence, digit span (maximum digits recalled, reflecting working memory), pairs matching (number correctly associated, reflects visual memory), and symbol digit substitution (use of a code to substitute symbols for digits). At baseline only fluid intelligence, prospective memory, digit span, and pairs matching were administered. Motor function was assessed using simple reaction speed in the cognitive battery (mean time to correctly identify matches in a task based on the “Snap” card game), handgrip strength (measured using a hydraulic hand dynamometer), and self-reported gait speed (slow/steady/brisk) at baseline.

Statistical analysis

All analyses were performed in R (version 3.6.0).

Observational

Separate linear regression models were used to assess the relationship between (1) alcohol consumption and χ /T2*; (2) alcohol consumption and liver iron; and (3) susceptibility and neurocognitive measures (ordered logistic regression for gait speed). Variables were quantile normalized to enforce Gaussianity in the data. Covariates previously associated with alcohol intake or iron levels and image-related confounders were included in the models. Age in years, sex, smoking status (reported as categorical variable: never/previous/current), body mass index (BMI) (calculated from measured height and weight), blood pressure (automated measurement), and cholesterol (from blood sample) were assessed at baseline. As heavy alcohol can impact blood pressure and cholesterol, models were also run excluding these variables to check we were not including non-confounders in our models [35]. Educational qualifications were self-reported in categories, as was household income. Historical job type was coded according to the Standard Occupational Classification 2000 [36], and Townsend Deprivation Index used as a continuous measure of deprivation based on census information. Diabetes was coded as a binary variable (presence of an ICD code for non-insulin dependent, insulin dependent, or nonspecified diabetes, E10, 11&14). The full set of imaging confounds was used as recently proposed [37] which include imaging site (3 sites), head motion, and head position.

For the subset with no missing data, dietary factors (meat, fish, bread, fruit, and vegetable consumption) and dietary iron supplementation were also included as covariates to test whether differences in diets according to alcohol intake were driving associations. Diet and supplement data were assessed at baseline via the questionnaire.

Analyses were also controlled for genetic polymorphisms prevalent in European populations that affect iron absorption and metabolism and have been linked to brain phenotypes [38]. A risk score was calculated by multiplying the dosage of 3 SNPs by their associations with serum iron (betas from GWAS [39]): rs1800562—in the HFE gene that is the main cause of hereditary hemochromatosis and carried by approximately 5% to 10% of Europeans [40]; rs1799945—also in HFE, carried by approximately 15% Europeans; and rs855791—which modulates hepicidin and approximately 53% Europeans are heterozygotes. No subjects were excluded on the basis of iron chelator prescription as none were documented. In a sensitivity analysis of females, menopause status at imaging was added as a covariate in an analysis of the brain region where the strongest observational associations were observed (putamen), as menstruation is protective against phenotypic expression of haemochromatosis [41]. In response to peer review comments, interactions between alcohol and age and sex were explored, as well as quadratic terms for alcohol to examine for nonlinear effects of alcohol.

For models with cognitive measures as the dependent variable, which are age-dependent, age interactions were included to explore whether iron altered age-related decline. Separate models were used to test cognitive performance at each time point. For models with χ/T2* as the dependent variable, an interaction between alcohol and liver iron was tested to assess for synergistic neurotoxic effects of alcohol and iron. To adjust for multiple testing, Bonferroni and false discovery rate (FDR, 5%) corrected p values were calculated. Correction methods were separately applied to models testing susceptibility-alcohol associations and those testing susceptibility-cognitive associations.

Causal mediation analysis (CMA) was performed to understand the mechanisms by which alcohol impacts brain iron [42,43]. CMA, unlike traditional mediation methods, defines, identifies, and estimates causal mediation effects without reference to a specific statistical model. Liver iron, reflecting systemic iron levels, was used as a mediator. The liver is the body’s primary iron store, and liver iron has better specificity for systemic iron stores than serum ferritin, which is an acute phase reactant liable to fluctuate according to inflammatory processes [15]. CMA tests the statistical significance of the direct from indirect (mediated) effects of alcohol on brain iron. CMA was run on participants with complete data. Two separate multiple linear regression models were run. First, with putamen susceptibility as the dependent variable, with alcohol, age, sex, Townsend Deprivation Index, income, qualifications, historical job code, diabetes, smoking, blood pressure, iron genetic risk score, BMI, cholesterol, and liver iron as covariates. In the second model, the mediator, liver T2*, was the dependent variable, with all covariates as in the first model. CMA was then run using nonparametric bootstrapping to generate confidence intervals (CIs) (1,000 simulations). Assumptions in CMA include no unmeasured confounding between the exposure and outcome, between the exposure and mediator, or between the mediator and the outcome. In response to peer review, the mediation analysis was extended to include all brain regions.

Two sets of post hoc analyses were performed. First, given the prominence of basal ganglia iron levels in relation to alcohol we observed, associations with available motor phenotypes (simple reaction speed, handgrip strength, and self-reported walking pace) were sought. Second, given observed associations between brain iron measures and executive function, we assessed associations between alcohol consumption and executive function (separately at time of scan and online follow up). In response to peer review, quadratic terms for alcohol were examined to test for nonlinear behaviour in the effects of alcohol consumption on cognitive function. We could not examine relationships with relevant diseases, for example, Parkinson’s due to insufficient numbers within the imaging sub study.

Mendelian randomization

MR aims to estimate causal relationships using observational data [44]. There are 3 key assumptions: (1) genetic variants are robustly associated with the exposure; (2) they share no common cause with the outcome; and (3) that genetic variants only affect the outcome through the exposure. Two sample linear MR was used to obtain estimates for the association between genetically predicted alcohol consumption/AUD and (1) brain susceptibility; (2) serum markers of iron homeostasis (as part of our investigation into the pathway by which alcohol influences brain iron). Analyses were conducted using MendelianRandomization (version 0.5.1) and TwoSampleMR (version 0.5.6) R packages. Variant harmonization ensured the association between SNPs and exposure and that between SNPs and the outcome reflected the same allele. Palindromic variants, where harmonization could not be confirmed, were excluded. Strands were aligned between studies. No proxies were used given the availability of SNPs across datasets. Several robust MR methods were performed to evaluate the consistency of the causal inference. Inverse variance weighted (IVW) analysis (multiplicative random effects) regresses the effect sizes of the variant-iron marker associations against the effect sizes of the variant-alcohol associations. The MR-Egger method uses a weighted regression with an unconstrained intercept to relax the assumption that all genetic variants are valid IVs (under the Instrument Strength Independent of Direct Effect (InSIDE) assumption) [45]. A nonzero intercept term can be interpreted as evidence of directional pleiotropy, where an instrument is independently associated with the outcome violating an MR assumption. The median and modal MR methods (reported in supplementary figures) are also more resistant to pleiotropy, as they are robust when up to 50% of genetic variants or more than not, respectively, are invalid. These methods are recommended in practice for sensitivity analyses as they require different assumptions to be satisfied, and therefore if estimates from such methods are similar, then any causal claim inferred is more credible. Analyses performed on one of the 3 cohorts (INTERVAL) meta-analysed in the serum iron GWAS was adjusted for alcohol consumption, so to check whether anti-conservative bias was impacting associations, a sensitivity analysis was run using weights derived solely from deCODE summary statistics that were unadjusted for alcohol. To adjust for multiple testing, Bonferroni and FDR (5%) corrected p values were calculated. Power calculations for MR analyses were based on an online calculator developed by one of the authors [46].

Results

Baseline characteristics of the included sample with complete data are shown in Table 1. Mean alcohol consumption was higher than current UK low risk guidelines (<14 units weekly), although within guidelines at the time for men (>21 units weekly pre-2016). Characteristics according to alcohol consumption are shown in S2 Table. Never drinkers comprised a higher proportion of females, lower blood pressure, and higher prevalence of diabetes compared to higher intake alcohol consumers.

Table 1. Baseline characteristics of UKB samples.

Alcohol is measured in UK units weekly. 1 unit = 8 grams ethanol. Educational qualifications were determined by self-report at baseline.

Sample with brain imaging N = 20,729 Sample with liver and brain imaging N = 6,936 Wider UKB sample N = 502,4891
Age 2 , years 54.8 ± 7.4 54.6 ± 7.3 56.53 ± 8.1
Sex, females n (%) 10,821 (48.6) 3,556 (51.3) 273,375 (54.4)
Townsend Deprivation Index −2.0 ± 2.6 −2.1 ± 2.6 −1.3 ± 3.1
Alcohol 2 , units weekly 17.7 ± 15.9 17.4 ± 15.6 17.1 ± 18.0
Current smoker, n (%) 1,390 (6.2) 444 (6.4) 52,977 (10.6)
Education, college or university degree, n (%) 10,041 (48.6) 3,452 (49.8) 161,158 (32.7)
A levels 2,732 (13.2) 967 (13.9) 55,321 (11.2)
No qualifications 1,107 (5.3) 341 (4.9) 85,269 (17.3)
BMI index 2 , kg/m 2 26.5 ± 4.0 26.1 ± 3.9 27.4 ± 4.8
Systolic blood pressure 2 , mm Hg 136.9 ± 18.6 136.8 ± 18.7 139.7 ± 19.7
Diastolic blood pressure, mm Hg 81.6 ± 10.5 81.4 ± 10.5 82.2 ± 10.7

1Total UKB sample. N varies according to missing data as mean/% was calculated on maximal sample size for each variable.

2Mean ± standard deviation.

BMI, body mass index; UKB, UK Biobank.

Associations with brain iron

Observational analyses

Alcohol consumption was associated with higher susceptibility in bilateral putamen (beta = 0.08, 95% CI: 0.06 to 0.09, p < 0.001), caudate (beta = 0.06, 95% CI: 0.04 to 0.06, p < 0.001), and substantia nigra (beta = 0.03, 95% CI: 0.02 to 0.05, p < 0.001) (Fig 2 and S3 Table). Alcohol was associated with lower iron in the thalamus (beta = −0.06, 95% CI: −0.07 to −0.04, p < 0.001). Drinking greater than 7 units weekly was associated with higher susceptibility for all brain regions, except the thalamus (Fig 3 and S4 Table). A sensitivity analysis with finer categorisation of alcohol intake revealed that associations were not observed at lower intakes than 7 units (compared to reference of <4 units weekly) (S5 Table). Menopause status did not associate with susceptibility in most brain regions in females, with the exception of slightly higher susceptibility in left thalamus (beta = 0.16, 95% CI: 0.04 to 0.27, p = 0.01) and left hippocampus (beta = 0.17, 95% CI: 0.05 to 0.29, p = 0.006) in females who had hysterectomies compared to premenopausal females (S6 Table). Controlling for menopause status did not alter associations between alcohol and susceptibility for any brain region (S6 Table), neither did excluding blood pressure and cholesterol as covariates (S3 Table). Inverse associations between thalamus susceptibility and alcohol were only observed in the heaviest drinking groups (Fig 3). There were significant interactions with age in bilateral putamen and caudate, but not with sex, smoking, or Townsend Deprivation Index (S3 Table). Quadratic terms for alcohol were not significant (S3 Table). In the subset with complete data (S7 and S8 Tables), additional adjustment for dietary factors, including frequency of red meat consumption, and dietary iron supplementation did not change the pattern of associations. Findings with T2* were broadly consistent, although associations with alcohol were only observed in putamen and caudate (S3 Table). These are 2 regions where correlation between T2* and susceptibility measures are more highly correlated (r = −0.58 to 0.75).

Fig 2. Associations between alcohol consumption and QSM phenotypes.

Fig 2

Associations surviving multiple testing comparisons are coloured, with colours corresponding to their region labels for ease of viewing. Estimates represent SDs and were generated from regression models adjusted for: age, sex, smoking, BMI, educational qualifications, Townsend Deprivation Index, household income, historical job code, diabetes, cholesterol, blood pressure, rs1800562, rs1799945, rs855791, and full set of image-related confounds. BMI, body mass index; FDR, false discovery rate; QSM, quantitative susceptibility mapping; SD, standard deviation.

Fig 3. Associations between alcohol consumption (quintiles) and QSM phenotypes.

Fig 3

Reference group is those consuming less than 7 units of alcohol weekly. Estimates generated from regression models adjusted for: age, sex, smoking, BMI, educational qualifications, Townsend Deprivation Index, household income, historical job code, diabetes, cholesterol, blood pressure, rs1800562, rs1799945, rs855791, and full set of image-related confounds. BMI, body mass index; LCI, lower confidence interval; N, number; QSM, quantitative susceptibility mapping; UCI, upper confidence interval.

Genetic analyses

Using 92 SNPs significantly associated with alcohol consumption, we found a positive association with left putamen susceptibility (IVW β = 0.25, 95% CI: 0.01 to 0.49, p = 0.04) and right hippocampus susceptibility (IVW β = 0.28, 95% CI: 0.05 to 0.50, p = 0.02) (Fig 4). However, neither passed FDR correction for multiple comparisons and there was evidence of heterogeneity between estimates (right hippocampus: Cochrane’s Q statistic = 121.4, df = 91, p = 0.018; Cochrane’s Q statistic = 137.4, df = 91, p = 0.001). Although alternative methods gave consistent estimates, 95% CIs were wide (S2 Fig). Genetically predicted AUD, instrumented with 24 SNPs, associated with higher right putamen susceptibility, although this did not survive multiple comparison correction (IVW β = 0.18, 95% CI: 0.001 to 0.35, p = 0.04) (S3 Fig). There were no other significant associations between genetically predicted AUD and other susceptibility measures. Based on a sample size of 29,579, R2 = 0.003 and α = 0.05, the MR analysis had 65.4% power to detect a causal effect of 0.25 SD.

Fig 4. Two-sample linear MR estimates for the causal effect of alcohol on susceptibility.

Fig 4

Genetic associations with alcohol consumption calculated from GWAS and Sequencing Consortium of Alcohol and Nicotine, associations with QSM image-derived phenotypes were derived from UKB. Effect estimates for alcohol consumption are per SD increase in genetically predicted log-transformed alcoholic drinks per week. Estimates from IVW analysis. IDP, quantitative susceptibility mapping imaging-derived phenotype; MR, mendelian randomization; QSM, quantitative susceptibility mapping; SNP, single nucleotide polymorphism; LCI, lower confidence interval; UCI, upper confidence interval; SD, standard deviation; UKB, UK Biobank.

Pathways from alcohol to brain iron

Higher systemic iron levels (liver iron) were found to partially mediate alcohol’s association with bilateral putamen and caudate susceptibility in CMA (Fig 5 and S9 Table). For example, a 1 SD increase in weekly alcohol consumption was associated with a 0.05 (95% CI: 0.02 to 0.07, p < 0.001) mg/g increase in liver iron (Fig 5). Approximately 1 mg/g increase in liver iron was associated with a 0.44 (95% CI: 0.35 to 0.52, p < 0.001) SD increase in left putamen susceptibility. In this sample, 32% (95% CI: 22 to 49, p < 0.001) of alcohol’s total effect on left putamen susceptibility was mediated via higher systemic iron levels (the indirect effect). The other 68% is mediated via other pathways (the direct effect). The proportion mediated was highest for the left caudate (48%, 95% CI: 0.30 to 0.94, p < 0.001) out of all brain regions. In contrast, we observed no significant mediation (after multiple testing correction) in the hippocampi, pallidum, accumbens, or substantia nigra (S9 Table).

Fig 5. Mediation of alcohol-related increases in left putamen susceptibility by liver iron.

Fig 5

N = 6,936 UKB participants. Numbers on the arrows are regression coefficients (with 95% CIs) reflecting: (a) change in liver iron (mg/g) for a 1 SD increase in alcohol intake weekly, (b) change in susceptibility (SD (95% CIs)) for a 1 mg/g increase in liver iron. The indirect and direct effects (standardized) derived from the mediation analysis are reported on the arrows linking alcohol to susceptibility. Models were adjusted for: age, sex, imaging site, Townsend Deprivation Index, educational qualifications, household income, historical job, blood pressure, BMI, cholesterol, smoking, and polygenic risk score for serum iron. BMI, body mass index; CI, confidence interval; SD, standard deviation; UKB, UK Biobank.

Alcohol consumption greater than 11 units weekly was associated with higher liver iron measured by MRI, a robust marker of systemic iron stores in males (β = 0.05, 95% CI: 0.01 to 0.08, p = 0.006) (S4 Fig). In females, higher liver iron was observed at intakes greater than 17 units weekly (β = 0.06, 95% CI: 0.03 to 0.08, p < 0.001). This is within currently defined UK “low risk” guidelines (<14 units weekly). Iron appeared to be a more sensitive liver marker of alcohol consumption than fat (PDFF) or fibrosis (cT1) (S5 and S6 Figs).

Using 24 SNPs significantly associated with AUD, there were statistically significant associations between genetically predicted AUD and serum iron (IVW β = 0.12, 95% CI: 0.05 to 0.19, p = 0.001) as well as transferrin saturation (IVW β = 0.11, 95% CI: 0.03 to 0.12, p = 0.006) that survive even stringent Bonferroni multiple testing correction (Fig 6). There was no evidence of heterogeneity using Cochrane’s Q (22.0, df = 23, p = 0.52). CIs for MR-Egger estimates were larger (serum iron β = 0.17, 95% CI: 0.009 to 0.34; transferrin saturation β = 0.16, 95% CI: −0.02 to 0.33) but broadly consistent (S7 Fig). Although estimates for associations between genetically predicted alcohol consumption (instrumented by 91 SNPs) and serum iron/transferrin saturation were of a similar magnitude, CIs were wider. In sensitivity analyses solely using data from deCODE which did not adjust their GWAS for alcohol, overall findings were unchanged (S8 Fig). We had >80% power to detect a causal effect of 0.13 SD.

Fig 6. Two-sample MR estimates of the causal effect of alcohol and alcohol use disorder on serum iron markers.

Fig 6

Genetic associations with: alcohol consumption calculated in GWAS and Sequencing Consortium of Alcohol and Nicotine, alcohol use disorder in Million Veterans Program and Psychiatric Genomics Consortium, and serum iron markers in deCODE, INTERVAL, and Danish Blood Donor Study. IVW estimates are shown. Effect estimates for alcohol consumption are per SD increase in genetically predicted log-transformed alcoholic drinkers per week, and for AUD having a diagnosis of AUD. AUD, alcohol use disorder; IVW, inverse variance weighted; LCI, lower confidence interval; MR, mendelian randomization; SD, standard deviation; SNP, single nucleotide polymorphisms; TIBC, total iron-binding capacity; UCI, upper confidence interval.

Clinical relevance of elevated brain iron

Higher hippocampal and pallidum susceptibility were associated with slower TMT duration (right side, TMT A: β = 2.20 × 10−2, 95% CI: 5.94 × 10−3 to 3.80 × 10−2, p = 0.038) and lower fluid intelligence (left: β = −2.98 × 10−2, 95% CI: −4.59 × 10−2 to −1.37 × 10−2, p < 0.001) (S10 Table). Associations were bilateral for the pallidum, but associations with fluid intelligence stronger for the left hippocampus.

Additionally, there were significant interactions between age and bilateral putamen (TMT A: duration β = 0.006, 95% CI: 0.003 to 0.008, p < 0.001; TMT B: duration β = 0.004, 95% CI: 0.002 to 0.006, p < 0.001), bilateral caudate (TMT A: β = 2.87 × 10−3, 95% CI: 7.67 × 10−4 to 4.97 × 10−3, p < 0.001; TMT B: β = 3.37 × 10−3, 95% CI: 1.25 × 10−3 to 5.49 × 10−3, p < 0.001), and right hippocampal (TMT A: β = 2.95 × 10−3, 95% CI: 8.43 × 10−4 to 5.05 × 10−3, p < 0.001) susceptibility in models of executive function (Fig 7A7C). Interactions with age were also evidence with putamen (β = −0.004, 95% CI: −0.006 to −0.002, p < 0.001), caudate (β = −2.33 × 10−3, 95% CI: −4.47 × 10−3 to −1.93 × 10−4, p < 0.001), and amygdala (β = −2.84 × 10−3, 95% CI: −4.97 × 10−3 to −7.04 × 10−4, p < 0.001) susceptibility and fluid intelligence. In both cases, age interactions were stronger for the right brain regions than left.

Fig 7. Associations with cognitive function.

Fig 7

(A) Putamen susceptibility-dependent effect of age on executive function (at time of scan). TMT durations and susceptibility are quantile normalized. (B) Caudate susceptibility-dependent effect of age on executive function. (C) Hippocampal susceptibility-dependent effect of age on executive function. (D) Reaction time (quantile normalized and fitted with restricted cubic spline, 5 knots) according to substantia nigra susceptibility. (E) and (F) Alcohol consumption-dependent effect on executive function (at online follow up). Alcohol intake is weekly units categorised in quintiles. Only intakes significantly different from reference group (<7 units) are plotted for clearer visualisation. Graphs generated from regression models controlled for: age, sex, imaging site, diabetes, smoking, income, education, BMI, blood pressure, cholesterol, and historical job type. Abbreviation: SD–standard deviation. BMI, body mass index; SD, standard deviation; TMT, trail-making test.

Neither substantia nigra nor thalamus susceptibility was associated with cognitive function. However, higher right substantia nigra susceptibility (β = 2.36 × 10−2, 95% CI: 7.64 × 10−3 to 3.95 × 10−2, p < 0.001), in addition to bilateral pallidum (right: β = 2.55 × 10−2, 95% CI: 9.40 × 10−3 to 4.15 × 10−2, p < 0.001), was associated with slower simple reaction time although not with other motor deficits (S10 Table).

There were no significant associations between putamen, caudate, hippocampus, or thalamus susceptibility and simple reaction time at the time of scan, or with age interactions in reaction time (S10 Table). Similarly, there were no significant associations between susceptibility measures and self-reported walking pace (OR = 1.00, 95% CI: 0.97 to 1.03). Grip strength was positively associated with bilateral putamen and caudate susceptibility (S10 Table), with significant sex interactions. Males appeared to drive the associations.

In a post hoc analysis, squared alcohol consumption was associated with slower TMT performance (alcohol β = −4.09 × 10−3, 95% CI: −0.02 to 0.01, p = 0.53; alcohol2 β = 0.01, 95% CI: 3.84 × 10−3 to 0.018, p = 0.003), and there were significant age by alcohol interactions (in those drinking 12 to 18 versus <7 units weekly β = −0.24, 95% CI: −0.40 to −0.09) (Fig 7E and 7F). However, this was only observed within the larger sample that participated in the later online follow up, preventing exploration of whether brain iron was mediating this pathway.

Discussion

Summary of findings

Alcohol consumption, including at low levels, was observationally associated with higher brain iron in multiple basal ganglia regions. There was some evidence supporting a causal relationship between genetically predicted alcohol consumption and putamen and hippocampus susceptibility, although this did not survive multiple testing correction. Alcohol was associated with both higher liver iron, an index of systemic iron load, and genetically predicted AUD associated with genetically predicted serum iron markers. Brain iron accumulation in drinkers was only partially mediated via higher systemic iron. Markers of higher brain iron (higher susceptibility) were associated with poorer executive function and fluid intelligence and slower reaction speed.

The accumulation of iron in the brain we observed in moderate drinkers overlaps with findings of an observational study in AUD. Higher putamen and caudate iron levels were described in a small study of males with AUD (n = 20) [9]. These individuals were drinking substantially more than our sample—a mean of 22 standard drinks per day (>37 units daily). In contrast, we observed associations in those drinking just >7 units per week. A recent phenome-wide association study of quantitative susceptibility in the same dataset reported significant associations in basal ganglia regions with higher frequency binge drinking [10]. Regional heterogeneity in iron concentrations is well described although the aetiology is not understood [47]. The basal ganglia, including the putamen [48], have some of the highest iron concentrations in the brain and suffer the greatest age-related increases [49]. Interestingly, we found significant alcohol-age interactions with susceptibility, suggesting that alcohol may magnify age effects on brain iron. We are mindful however that within UKB, changes with age could represent a cohort effect. In this sample, associations with susceptibility and T2* measures were observed at lower alcohol intakes in females. In haemochromatosis, females are relatively protected against the clinical manifestations of iron overload through menstrual blood loss [50]. The majority of our included sample, however, (70%) was postmenopausal and menopause status did not alter alcohol–brain iron associations. Sex differences in alcohol metabolism therefore may be responsible. These findings do not support current UK “low risk” drinking guidelines that recommend identical amounts for males and females [51]. We found some support for a causal relationship between alcohol consumption and susceptibility in the putamen and hippocampus, and between AUD and putamen susceptibility in MR analysis. Although these associations did not survive multiple comparisons correction, they are in the same direction as the highly significant observational associations. Associations between genetically predicted alcohol and susceptibility in other regions were not significant. We suspect this results from our limited power to detect small associations despite the sample size, given that the genetic instruments explain less than 1% of the phenotypic variation in alcohol consumption [29]. Furthermore, weak instrument bias, in the direction of the null, may be contributing [52]. Using UKB for our calculations, about one third of SNPs we used to instrument alcohol consumption had F statistics <10 (S11 Table).

Our MR results provide evidence for a causal role of AUD in increasing serum iron and transferrin saturation, a sensitive marker of iron overload [53]. While genetically predicted alcohol use was not significantly associated with ferritin, this mirrors findings in early haemochromatosis, where ferritin levels can be normal and transferrin saturation is the earliest marker of iron overload [54]. The associations we found with liver iron, a reliable marker of systemic iron stores, were consistent with the serum results. In fact, in our study, which we believe the largest investigation of alcohol and liver iron by an order of magnitude [55], iron levels were the most sensitive liver marker of alcohol-related damage. Alcohol suppresses hepcidin production, the major hormone-regulating iron homeostasis [56]. This suppression increases intestinal absorption of dietary iron [57] and limits export of iron from hepatocytes. In our CMA, higher systemic iron levels only explained 32% of alcohol’s effects on brain iron, suggesting other mechanisms are also involved. These could include an increase of blood–brain barrier permeability to iron, in turn mediated by reduced thiamine that commonly occurs in AUD due to a combination of inadequate dietary intake, reduced absorption, and metabolic changes [58,59]. In cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) patients, iron leakage has been linked to blood–brain barrier permeability [60]. Other possible mechanisms include dopamine surges following alcohol ingestion or chronic inflammatory processes [61]. The alternative possibility is that individuals with higher brain iron drink more alcohol. One potential mechanism for this is that tyrosine hydroxylase, an enzyme in the dopamine synthesis pathway, is iron dependent [62]. Dopamine has been linked to alcohol cravings in dependence [63]. For this reason, we used MR to support/refute the observational analyses.

Higher putamen and caudate susceptibility interacted with age in predicting executive function and fluid intelligence, but not with simple motor tasks. Most, but not all, previous work has highlighted the importance of the putamen to complex motor tasks [64]. Interestingly, both trail making and the fluid intelligence tasks were performed within a time limit, and perhaps represent a measure of motor response linked to cognition, rather than a simple motor response. TMTs appear to be among the most sensitive to aging effects in the UKB cognitive battery [34]. Frontal dysfunction is well described in chronic heavy alcohol use [65]. Several putamen metrics have been associated with executive function, including blood flow [66], structural atrophy [67], and functional connectivity [68]. Iron accumulation in the putamen has also been described in developmental stuttering [69] and CADASIL [70]. Although most studies of dietary iron and cognition have been in children or anaemic individuals, there is some evidence that high dietary iron associates with poorer cognition [71]. While sex differences in cognition have been described [72], it is difficult to disentangle differing iron levels from hormonal factors in the aetiology. How iron deposition could result in cognitive deficits requires further investigation. Iron co-localises in the brain with tau and beta amyloid [73], and can cause apoptosis and ferroptosis [74]. Higher substantia nigra susceptibility associated with slower reaction speed. The substantia nigra plays a vital role in movement regulation, and iron deposition in the substantia nigra has been linked to Parkinson’s disease [75,76], a disorder with marked impairments in reaction speed [77].

To our knowledge, this is the largest study of moderate alcohol consumption and multiorgan iron accumulation. It is also the first study to use MR to investigate causality of alcohol on serum and brain iron.

We did not observe widespread associations between susceptibility or T2* and other cognitive tests or self-reported motor measures. Brain iron is likely to be an early marker of disease, and participants may have been examined too early in the process to detect clinical manifestations. Additionally, we are not likely to have captured the best phenotypes to assess basal ganglia function in the absence of objective motor measurements such as gait speed or a pegboard test. Self-reported walking speed may poorly approximate actual motor function. The cognitive tests were limited in scope and concerns have been raised about the reliability of the tests used [34]. Healthy selection biases in UKB are well described, and are likely magnified in the imaging subsample, but will equally bias the study towards null results [78]. Furthermore, associations in UKB seem to track with those observed in representative cohorts [79].

Changes in T2* and χ can reflect changes in iron but also myelin [80,81]. One key difference between T2* and χ is that iron (paramagnetic) and myelin (diamagnetic) have the opposite effect on χ in QSM, but the same effect on T2*. Hence, the positive associations we observed between χ and alcohol could theoretically be driven by increased iron or reduced myelin. If the latter, then alcohol would also be positively associated with T2* (reduced myelin leads to longer T2*). In contrast, we observed negative associations between T2* and alcohol. This supports our interpretation that increased iron is driving our results, given one highly plausible assumption, that alcohol does not increase grey matter myelination [82,83].

Partial volume effects could confound associations between hippocampal susceptibility and alcohol. For example, hippocampal atrophy, previously observed in drinkers [1], could be conflated with changes in χ. However, this would tend to reduce estimated χ. Alcohol was self-reported, but this is the only feasible method to ascertain intake at scale. Serum markers of iron homeostasis were not directly measured in UKB. Although analyses were controlled for the strongest SNPs associated with serum iron, these are likely to explain a low proportion of the variance. MR techniques rely on a number of assumptions that we have tried to test where possible, but residual uncertainty inevitably remains. Estimates were calculated in European individuals, but it is unclear how they generalise to other populations. MR estimates the effect of lifelong exposure, which does not necessarily translate into potential effects resulting from an intervention in adult life. Liver T2* has been useful in some studies to monitor iron overload, but further validation of this biomarker as a diagnostic marker of iron overload is needed [84]. Genetic variants explain a low variance of alcohol traits. Therefore, our analysis within the imaging sample, despite its large size, has limited power to detect small effects. The power for the larger serum iron measures was greater. For this reason, although nonlinear relationships between alcohol and health outcomes are of interest, we limited MR analyses to linear models. Mediation analysis is not experimental in design, and relies on intervention–outcome, intervention–mediator, and mediator–outcome effects being unconfounded to permit valid causal inferences. Alcohol exposure prior to study baseline (left truncation) may bias observational estimates [85]. In this study, liver and brain iron were measured at the same time, meaning reverse causation is possible. However, it is difficult to conceive of a plausible mechanism by which brain iron levels could substantially affect systemic iron.

Never drinkers appeared to have the lowest levels of brain iron. This is in keeping with our earlier work indicating there may be no safe level of alcohol consumption for brain health [20]. Moderate drinking is highly prevalent, so if elevated brain iron is confirmed as a mechanism by which alcohol leads to cognitive decline, there are opportunities for intervention on a population scale. Iron chelation therapy is already being investigated for Alzheimer’s and Parkinson’s diseases [17,18,86]. Furthermore, if reduced thiamine is mediating brain iron accumulation, then interventions to improve nutrition and thiamine supplementation could be extended beyond harmful and dependent drinkers, as is currently recommended [87], to moderate drinkers.

Conclusions

In this large sample of UKB participants, we find evidence for elevated susceptibility and reduced T2* in basal ganglia regions with even moderate alcohol consumption. These changes likely reflect increased iron concentrations. Alcohol-related brain iron may be partially mediated by higher systemic iron levels, but it is likely there are additional mechanisms involved. Poorer executive function and fluid intelligence and slower reaction speeds were seen with markers of higher basal ganglia iron. Brain iron accumulation is a possible mechanism for alcohol-related cognitive decline.

Supporting information

S1 Checklist. STROBE checklist of recommended items to address in cohort studies.

(DOCX)

S2 Checklist. STROBE-MR checklist of recommended items to address in reports of mendelian randomization studies.

(DOCX)

S1 Fig. Flow chart of participants included in analyses.

UKB, UK Biobank; QSM, quantitative susceptibility mapping.

(PNG)

S2 Fig. Comparison of different 2-sample MR methods for estimating the causal effects of alcohol on brain susceptibility.

Genetic associations with alcohol consumption were calculated in GWAS and Sequencing Consortium of Alcohol and Nicotine, and genetic associations with susceptibility imaging-derived phenotypes from UKB. Effect estimates for alcohol consumption are per standard deviation increase in genetically predicted log-transformed drinks per week. LCI, lower confidence interval; MR, mendelian randomization; SNP, single nucleotide polymorphisms; UCI, upper confidence interval.

(PNG)

S3 Fig. Two-sample MR randomization analyses to estimate the causal effects of alcohol use disorder on brain susceptibility.

MR estimates (2-sample design) for associations between genetically predicted alcohol use disorder (Million Veterans Program and Psychiatric Genomics Consortium) and susceptibility imaging-derived phenotypes (UK Biobank) in inverse-variance weighted analysis. LCI, lower confidence interval; MR, mendelian randomization; SNP, single nucleotide polymorphism; UCI, upper confidence interval.

(PNG)

S4 Fig. Observational associations between weekly alcohol consumption (quintiles) and liver iron (mg/g).

Reference group is those drinking <7 units (56 g) weekly. Estimates generated from regression models adjusted for: age, educational qualifications, Townsend Deprivation Index, household income, historical job code, smoking, imaging site, diabetes mellitus, BMI, blood pressure, cholesterol, dietary iron, rs1800562, rs1799945, and rs855791. BMI, body mass index; LCI, lower confidence interval; UCI, upper confidence interval.

(PNG)

S5 Fig. Observational associations between weekly alcohol consumption (quintiles) and liver protein density fat fraction (%).

Estimates are adjusted for age, sex, smoking, BMI, cholesterol, blood pressure, diabetes, educational qualifications, Townsend Deprivation Index, household income, and historical job type. BMI, body mass index; LCI, lower confidence interval; UCI, upper confidence interval.

(PNG)

S6 Fig. Observational associations between weekly alcohol consumption (quintiles) and liver cT1 (milliseconds), a marker of inflammation/fibrosis.

Estimates are adjusted for: age, sex, smoking, BMI, cholesterol, blood pressure, diabetes, educational qualifications, Townsend Deprivation Index, household income, and historical job type. All estimates are within the normal reference range [88]. BMI, body mass index; LCI, lower confidence interval; UCI, upper confidence interval.

(PNG)

S7 Fig. Comparison of different two-sample MR estimates of the causal effect of alcohol used disorder on serum markers of iron homeostasis.

Genetic associations of alcohol use disorder generated in the Million Veterans Program and Psychiatric Genomics Consortium and of serum markers of iron homeostasis from deCODE, INTERVAL, and the Danish Blood Donor Study. LCI, lower confidence interval; MR, mendelian randomization; SNP, single nucleotide polymorphism; TIBC, total iron binding capacity; UCI, upper confidence interval.

(PNG)

S8 Fig. Two-sample MR estimates of the causal effects of alcohol consumption and alcohol use disorder on serum iron markers.

Genetically predicted alcohol consumption was log-transformed drinks per week, generated from GWAS and Sequencing Consortium of Alcohol and Nicotine. Genetic associations with alcohol use disorder were generated from the Million Veterans Program and Psychiatric Genomics Consortium. Genetic associations with serum iron markers were calculated in cohorts that did not adjust for alcohol in their genome-wide association study (DECODE unless otherwise marked). LCI, lower confidence interval; SNP, single nucleotide polymorphism; UCI, upper confidence interval.

(PNG)

S1 Table. Summary statistics sources for genetic associations with alcohol intake, alcohol use disorder, serum iron measures, and brain iron measures.

(XLSX)

S2 Table. Baseline characteristics according to alcohol intake.

(XLSX)

S3 Table. Observational associations between alcohol consumption and brain iron measures.

(XLSX)

S4 Table. Unadjusted observational associations between weekly alcohol intake (quintiles) and brain susceptibility.

(XLSX)

S5 Table. Observational associations between weekly alcohol intake (octiles) and brain susceptibility.

(XLSX)

S6 Table. Observational associations between (1) alcohol intake and brain susceptibility controlling for menopause status; and (2) susceptibility and menopause status.

(XLSX)

S7 Table. Baseline characteristics for sample with diet and iron supplementation data.

(XLSX)

S8 Table. Observational associations between weekly alcohol intake (quintiles) and brain susceptibility, additionally adjusted for diet and iron supplementation.

(XLSX)

S9 Table. Mediation analyses for all brain regions.

(XLSX)

S10 Table. Observational associations between brain susceptibility and cognitive test performance at time of the scan.

(XLSX)

S11 Table. F statistics for genetic instruments for alcohol consumption.

(XLSX)

Abbreviations

AUD

alcohol use disorder

BMI

body mass index

CMA

causal mediation analysis

CI

confidence interval

cT1

corrected T1

FDR

false discovery rate

GWAS

genome-wide association study

IDP

image-derived phenotype

IVW

inverse variance weighted

MR

mendelian randomization

PDFF

proton density fat fraction

QSM

quantitative susceptibility mapping

SD

standard deviation

SNP

single nucleotide polymorphism

swMRI

susceptibility-weighted MRI

TMT

trail-making test

UKB

UK Biobank

Data Availability

Imaging and observational data underlying the results presented are available from the UK Biobank upon successful application (https://www.ukbiobank.ac.uk/enable-yourresearch/apply-for-access). Genetic summary statistics for serum iron measures are freely available (https://www.decode.com/summarydata/), as are GSCAN summary statistics (https://genome.psych.umn.edu/index.php/GSCAN). Summary statistics for alcohol use disorder are available upon application through dfGaP at accession no. phs0016732.v3.p1 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi study_id=phs001672.v3.p1).

Funding Statement

AT is supported by a Wellcome Trust (https://wellcome.org/) fellowship (216462/Z/19/Z). CW is funded, in part, by the China Scholarship Council (CSC, https://www.chinesescholarshipcouncil.com/). KPE is funded by the UK Medical Research Council (https://mrc.ukri.org/, G1001354 & MR/K013351/1) and the European Commission (https://ec.europa.eu/programmes/horizon2020/en/home, Horizon 2020 732592). CM is funded by the NIHR Oxford Biomedical Research Centre (IS-BRC-1215-20008) and the BHF Centre of Research Excellence, Oxford. JG, DL and HZ are supported by the US Department of Veterans Affairs (https://www.research.va.gov/funding/, I01CX001849). SBu is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (https://royalsociety.org/, 204623/Z/16/Z). SBe was supported by the British Heart Foundation (https://www.bhf.org.uk/for-professionals/information-for-researchers/what-we-fund, RG/16/4/32218) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). MH is supported by the Wellcome Trust (206330/Z/17/Z) and NIHR Oxford Biomedical Research Centre (IS-BRC-1215-20008). SS is supported by a Wellcome Trust Collaborative Award 215573/Z/19/Z. KLM is supported by a Wellcome Trust Senior Research Fellowship (202788/Z/16/Z). TN is supported by the Li Ka Shing Centre for Health Information and Discovery, an NIH grant (https://www.nih.gov/, TN: R01EB026859), the National Institute for Health Research Oxford Biomedical Research Centre (BRC-1215-20014), and a Wellcome Trust award (TN: 100309/Z/12/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Topiwala A, Allan CL, Valkanova V, Zsoldos E, Filippini N, Sexton C, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017;357. doi: 10.1136/bmj.j2353 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth WT Jr, Mittleman MA, Siscovick DS. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA. 2003;289(11):1405–13. doi: 10.1001/jama.289.11.1405 [DOI] [PubMed] [Google Scholar]
  • 3.Organization WH. Global status report on alcohol and health 2018: executive summary. World Health Organization; 2018. Available from: https://www.who.int/publications-detail-redirect/9789241565639. [Google Scholar]
  • 4.Visontay R, Rao RT, Mewton L. Alcohol use and dementia: new research directions. Curr Opin Psychiatry. 2021;34(2):165–70. doi: 10.1097/YCO.0000000000000679 [DOI] [PubMed] [Google Scholar]
  • 5.Listabarth S, König D, Vyssoki B, Hametner S. Does thiamine protect the brain from iron overload and alcohol-related dementia? Alzheimers Dement. 2020;16(11):1591–5. doi: 10.1002/alz.12146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Nielsen J, Jensen LN, Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry. 1995;59(3):318–21. doi: 10.1136/jnnp.59.3.318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lane DJ, Ayton S, Bush AI. Iron and Alzheimer’s disease: an update on emerging mechanisms. J Alzheimers Dis. 2018;64(s1):S379–S95. doi: 10.3233/JAD-179944 [DOI] [PubMed] [Google Scholar]
  • 8.Oakley A, Collingwood J, Dobson J, Love G, Perrott H, Edwardson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurologija. 2007;68(21):1820–5. doi: 10.1212/01.wnl.0000262033.01945.9a [DOI] [PubMed] [Google Scholar]
  • 9.Juhás M, Sun H, Brown MR, Mackay MB, Mann KF, Sommer WH, et al. Deep grey matter iron accumulation in alcohol use disorder. Neuroimage. 2017;148:115–22. doi: 10.1016/j.neuroimage.2017.01.007 [DOI] [PubMed] [Google Scholar]
  • 10.Wang C, Martins-Bach AB, Alfaro-Almagro F, Douaud G, Klein JC, Llera A, et al. Phenotypic and genetic associations of quantitative magnetic susceptibility in UK Biobank brain imaging. Nat Neurosci. 2021. 10.1038/s41593-022-01074-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson K. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34(4):275–8. doi: 10.1136/jmg.34.4.275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Whitfield JB, Zhu G, Heath AC, Powell L, Martin N. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res. 2001;25(7):1037–45. [PubMed] [Google Scholar]
  • 13.Duane P, Raja K, Simpson R, Peters T. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol. 1992;27(5):539–44. [PubMed] [Google Scholar]
  • 14.Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterologia. 2004;126(5):1293–301. [DOI] [PubMed] [Google Scholar]
  • 15.Barry M, Sherlock S. Measurement of liver-iron concentration in needle-biopsy specimens. Lancet. 1971;297(7690):100–3. doi: 10.1016/s0140-6736(71)90838-5 [DOI] [PubMed] [Google Scholar]
  • 16.Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982;307(27):1671–5. doi: 10.1056/NEJM198212303072703 [DOI] [PubMed] [Google Scholar]
  • 17.Bagwe-Parab S, Kaur G. Molecular targets and therapeutic interventions for iron induced neurodegeneration. Brain Res Bull. 2020;156:1–9. doi: 10.1016/j.brainresbull.2019.12.011 [DOI] [PubMed] [Google Scholar]
  • 18.Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9. doi: 10.1038/s41586-018-0579-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Topiwala A, Ebmeier KP, Maullin-Sapey T, Nichols TE. No safe level of alcohol consumption for brain health: observational cohort study of 25,378 UK Biobank participants. Neuroimage Clin. 2022;35:103066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Naimi T, Chikritzhs T, Stockwell T. Commentary on Di Castelnuovo et al: Implications of using low volume drinkers instead of never drinkers as the reference group. Addiction. 2022;117(2):327–9. doi: 10.1111/add.15692 [DOI] [PubMed] [Google Scholar]
  • 22.Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JL, Griffanti L, Douaud G, et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage. 2018;166:400–24. doi: 10.1016/j.neuroimage.2017.10.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.De Barros A, Arribarat G, Combis J, Chaynes P, Péran P. Matching ex vivo MRI with iron histology: pearls and pitfalls. Front Neuroanat. 2019;13:68. doi: 10.3389/fnana.2019.00068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld EJ. Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magn Reson Imaging. 2015;33(6):761–7. doi: 10.1016/j.mri.2015.02.016 [DOI] [PubMed] [Google Scholar]
  • 25.Mckay A, Wilman HR, Dennis A, Kelly M, Gyngell ML, Neubauer S, et al. Measurement of liver iron by magnetic resonance imaging in the UK Biobank population. PLoS ONE. 2018;13(12):e0209340. doi: 10.1371/journal.pone.0209340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564–73. doi: 10.1007/s00330-019-06072-4 [DOI] [PubMed] [Google Scholar]
  • 27.Reeder SB, Pineda AR, Wen Z, Shimakawa A, Yu H, Brittain JH, et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med. 2005;54(3):636–44. doi: 10.1002/mrm.20624 [DOI] [PubMed] [Google Scholar]
  • 28.Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64(2):308–15. doi: 10.1016/j.jhep.2015.10.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237–44. doi: 10.1038/s41588-018-0307-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7):597–608. doi: 10.1002/gepi.21998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhou H, Sealock JM, Sanchez-Roige S, Clarke T-K, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23(7):809–18. doi: 10.1038/s41593-020-0643-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bell S, Rigas AS, Magnusson MK, Ferkingstad E, Allara E, Bjornsdottir G, et al. A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. Commun Biol. 2021;4(1):1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Smith SM, Douaud G, Chen W, Hanayik T, Alfaro-Almagro F, Sharp K, et al. An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank. Nat Neurosci. 2021;24(5):737–45. doi: 10.1038/s41593-021-00826-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. PLoS ONE. 2020;15(4):e0231627. doi: 10.1371/journal.pone.0231627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hernández-Díaz S, Schisterman EF, Hernán MA. The birth weight “paradox” uncovered? Am J Epidemiol. 2006;164(11):1115–20. doi: 10.1093/aje/kwj275 [DOI] [PubMed] [Google Scholar]
  • 36.Statistics OON. Standard Occupational Classification 2000: SOC 2000. 2000. Available from: https://www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalclassificationsoc/socarchive. [Google Scholar]
  • 37.Alfaro-Almagro F, Mccarthy P, Afyouni S, Andersson JL, Bastiani M, Miller KL, et al. Confound modelling in UK Biobank brain imaging. Neuroimage. 2021;224:117002. doi: 10.1016/j.neuroimage.2020.117002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Atkins JL, Pilling LC, Heales CJ, Savage S, Kuo C-L, Kuchel GA, et al. Hemochromatosis Mutations, Brain Iron Imaging, and Dementia in the UK Biobank Cohort. J Alzheimers Dis. 2021;79(3):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Benyamin B, Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, et al. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun. 2014;5(1):1–11. doi: 10.1038/ncomms5926 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Medicine NLO. Reference SNP (rs) report. 2021. Available from: https://www.ncbi.nlm.nih.gov/snp/rs20320. [Google Scholar]
  • 41.Brissot P, Pietrangelo A, Adams PC, De Graaff B, Mclaren CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers. 2018;4(1):1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Imai K, Keele L, Tingley D, Yamamoto T. Causal mediation analysis using R. Advances in social science research using R. Springer. 2010:129–54. [Google Scholar]
  • 43.Lee H, Herbert RD, Mcauley JH. Mediation analysis. JAMA. 2019;321(7):697–8. doi: 10.1001/jama.2018.21973 [DOI] [PubMed] [Google Scholar]
  • 44.Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30–42. doi: 10.1093/ije/dyh132 [DOI] [PubMed] [Google Scholar]
  • 45.Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25. doi: 10.1093/ije/dyv080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Burgess S. Online sample size and power calculator for Mendelian randomization. Available from: https://sb452.shinyapps.io/power.
  • 47.Ramos P, Santos A, Pinto NR, Mendes R, Magalhães T, Almeida A. Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol. 2014;28(1):13–7. doi: 10.1016/j.jtemb.2013.08.001 [DOI] [PubMed] [Google Scholar]
  • 48.Mcallum EJ, Hare DJ, Volitakis I, Mclean CA, Bush AI, Finkelstein DI, et al. Regional iron distribution and soluble ferroprotein profiles in the healthy human brain. Prog Neurobiol. 2020;186:101744. doi: 10.1016/j.pneurobio.2019.101744 [DOI] [PubMed] [Google Scholar]
  • 49.Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage. 2012;59(3):2625–35. doi: 10.1016/j.neuroimage.2011.08.077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Pilling LC, Tamosauskaite J, Jones G, Wood AR, Jones L, Kuo C-L, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ. 2019;364. doi: 10.1136/bmj.k5222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Care DOHaS. UK chief medical officers’ guidelines on how to keep health risks from drinking alcohol to a low level. 2016. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/489795/summary.pdf. [Google Scholar]
  • 52.Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755–64. doi: 10.1093/ije/dyr036 [DOI] [PubMed] [Google Scholar]
  • 53.Elsayed M, Sharif M, Stack A. Transferrin saturation: a body iron biomarker. Adv Clin Chem. 2016;75:71–97. doi: 10.1016/bs.acc.2016.03.002 [DOI] [PubMed] [Google Scholar]
  • 54.Mclaren CE, Mclachlan GJ, Halliday JW, Webb SI, Leggett BA, Jazwinska EC, et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterologia. 1998;114(3):543–9. [DOI] [PubMed] [Google Scholar]
  • 55.Schutte R, Papageorgiou M, Najlah M, Huisman HW, Ricci C, Zhang J, et al. Drink types unmask the health risks associated with alcohol intake–prospective evidence from the general population. Clin Nutr. 2020;39(10):3168–74. doi: 10.1016/j.clnu.2020.02.009 [DOI] [PubMed] [Google Scholar]
  • 56.Ohtake T, Saito H, Hosoki Y, Inoue M, Miyoshi S, Suzuki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res. 2007;31:S2–8. doi: 10.1111/j.1530-0277.2006.00279.x [DOI] [PubMed] [Google Scholar]
  • 57.Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–43. doi: 10.1016/j.bbamcr.2012.01.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Harata N, Iwasaki Y. Evidence for early blood-brain barrier breakdown in experimental thiamine deficiency in the mouse. Metab Brain Dis. 1995;10(2):159–74. doi: 10.1007/BF01991863 [DOI] [PubMed] [Google Scholar]
  • 59.Martin PR, Singleton CK, Hiller-Sturmhöfel S. The role of thiamine deficiency in alcoholic brain disease. Alcohol Res Health. 2003;27(2):134. [PMC free article] [PubMed] [Google Scholar]
  • 60.Uchida Y, Kan H, Sakurai K, Arai N, Inui S, Kobayashi S, et al. Iron leakage owing to blood–brain barrier disruption in small vessel disease CADASIL. Neurologija. 2020;95(9):e1188–e98. doi: 10.1212/WNL.0000000000010148 [DOI] [PubMed] [Google Scholar]
  • 61.Yoder KK, Constantinescu CC, Kareken DA, Normandin MD, Cheng TE, O’connor SJ, et al. Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. Alcohol Clin Exp Res. 2007;31(6):965–73. doi: 10.1111/j.1530-0277.2007.00390.x [DOI] [PubMed] [Google Scholar]
  • 62.Ramsey AJ, Hillas PJ, Fitzpatrick PF. Characterization of the active site iron in tyrosine hydroxylase: Redox states of the iron. J Biol Chem. 1996;271(40):24395–400. doi: 10.1074/jbc.271.40.24395 [DOI] [PubMed] [Google Scholar]
  • 63.Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grüsser-Sinopoli SM, et al. Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry. 2004;161(10):1783–9. doi: 10.1176/appi.ajp.161.10.1783 [DOI] [PubMed] [Google Scholar]
  • 64.Delong M. Putamen: activity of single units during slow and rapid arm movements. Science. 1973;179(4079):1240–2. doi: 10.1126/science.179.4079.1240 [DOI] [PubMed] [Google Scholar]
  • 65.Kopelman MD. Frontal dysfunction and memory deficits in the alcoholic Korsakoff syndrome and Alzheimer-type dementia. Brain. 1991;114(1):117–37. [PubMed] [Google Scholar]
  • 66.O’carroll REHPC, Ebmeier KP, Dougall N, Murray C, Jjk B, Iad B, et al. Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet. 1991;337(May 25). doi: 10.1016/0140-6736(91)92920-w [DOI] [PubMed] [Google Scholar]
  • 67.Li P, Wang Y, Jiang Y, Chen X, Dong Q, Cui M. Association between cognition and gait in elderly people: The putamen as a shared substrate: Neuropsychology/Neuropsychological correlates of physiologic markers of cognitive decline/Dementia. Alzheimers Dement. 2020;16:e041905. [Google Scholar]
  • 68.Fjell AM, Sneve MH, Grydeland H, Storsve AB, Walhovd KB. The disconnected brain and executive function decline in aging. Cereb Cortex. 2017;27(3):2303–17. doi: 10.1093/cercor/bhw082 [DOI] [PubMed] [Google Scholar]
  • 69.Cler GJ, Krishnan S, Papp D, Wiltshire CE, Chesters J, Watkins KE. Elevated iron concentration in putamen and cortical speech motor network in developmental stuttering. Brain. 2021;144(10):2979–84. doi: 10.1093/brain/awab283 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Sun C, Wu Y, Ling C, Xie Z, Kong Q, Fang X, et al. Deep gray matter Iron deposition and its relationship to clinical features in cerebral autosomal dominant Arteriopathy with subcortical infarcts and leukoencephalopathy patients: a 7.0-T magnetic resonance imaging study. Stroke. 2020;51(6):1750–7. doi: 10.1161/STROKEAHA.119.028812 [DOI] [PubMed] [Google Scholar]
  • 71.Shi Z, Li M, Wang Y, Liu J, El-Obeid T. High iron intake is associated with poor cognition among Chinese old adults and varied by weight status—a 15-y longitudinal study in 4852 adults. Am J Clin Nutr. 2019;109(1):109–16. doi: 10.1093/ajcn/nqy254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Munro CA, Winicki JM, Schretlen DJ, Gower EW, Turano KA, Muñoz B, et al. Sex differences in cognition in healthy elderly individuals. Neuropsychol Dev Cogn. 2012;19(6):759–68. doi: 10.1080/13825585.2012.690366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Van Bergen J, Li X, Hua J, Schreiner S, Steininger S, Quevenco F, et al. Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Sci Rep. 2016;6(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. doi: 10.1016/j.cell.2012.03.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Gorell J, Ordidge R, Brown G, Deniau J, Buderer N, Helpern J. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurologija. 1995;45(6):1138–43. doi: 10.1212/wnl.45.6.1138 [DOI] [PubMed] [Google Scholar]
  • 76.Sofic E, Paulus W, Jellinger K, Riederer P, Youdim M. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem. 1991;56(3):978–82. doi: 10.1111/j.1471-4159.1991.tb02017.x [DOI] [PubMed] [Google Scholar]
  • 77.Cooper JA, Sagar HJ, Tidswell P, Jordan N. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson’s disease. Brain. 1994;117(3):517–29. doi: 10.1093/brain/117.3.517 [DOI] [PubMed] [Google Scholar]
  • 78.Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186(9):1026–34. doi: 10.1093/aje/kwx246 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ. 2020;368. doi: 10.1136/bmj.m131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Stüber C, Morawski M, Schäfer A, Labadie C, Wähnert M, Leuze C, et al. Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. Neuroimage. 2014;93:95–106. doi: 10.1016/j.neuroimage.2014.02.026 [DOI] [PubMed] [Google Scholar]
  • 81.Duyn JH, Schenck J. Contributions to magnetic susceptibility of brain tissue. NMR Biomed. 2017;30(4):e3546. doi: 10.1002/nbm.3546 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Kilpatrick LA, Alger JR, O’neill J, Joshi SH, Narr KL, Levitt JG, et al. Impact of prenatal alcohol exposure on intracortical myelination and deep white matter in children with attention deficit hyperactivity disorder. Neuroimage Rep. 2022;2(1):100082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Ozer E, Sarioglu S, Güre A. Effects of prenatal ethanol exposure on neuronal migration, neuronogenesis and brain myelination in the mice brain. Clin Neuropathol. 2000;19(1):21–5. [PubMed] [Google Scholar]
  • 84.LA SM, Vlachaki E, Paschos P, Athanasiadou E, Vm M, Murad M, et al. Accuracy of magnetic resonance imaging in diagnosis of liver iron overload: a systematic review and meta-analysis. Gastroenterol Hepatol. 2015;13(1):55–63. [DOI] [PubMed] [Google Scholar]
  • 85.Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5. doi: 10.1016/j.jclinepi.2016.04.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Singh YP, Pandey A, Vishwakarma S, Modi G. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases. Mol Divers. 2019;23(2):509–26. doi: 10.1007/s11030-018-9878-4 [DOI] [PubMed] [Google Scholar]
  • 87.Nice. Alcohol-use disorders: diagnosis and management of physical complications. 2017. Available from: https://www.nice.org.uk/guidance/cg100. [PubMed] [Google Scholar]
  • 88.Mojtahed A, Kelly C, Herlihy A, Kin S, Wilman H, Mckay A, et al. Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases. Abdom Radiol. 2019;44(1):72–84. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Caitlin Moyer

12 Feb 2022

Dear Dr Topiwala,

Thank you for submitting your manuscript entitled "Impact of moderate alcohol consumption on brain iron and cognition: observational and genetic analyses" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Feb 16 2022 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission.

Kind regards,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

Decision Letter 1

Caitlin Moyer

23 Mar 2022

Dear Dr. Topiwala,

Thank you very much for submitting your manuscript "Impact of moderate alcohol consumption on brain iron and cognition: observational and genetic analyses" (PMEDICINE-D-22-00417R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to four independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Apr 13 2022 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

1. Competing Interests: Please add this statement to the manuscript's Competing Interests: "SB is a paid statistical consultant on PLOS Medicine's statistical board."

2. Data Availability Statement: The Data Availability Statement (DAS) requires revision. For each data source used in your study:

a) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number).

b) If the data are owned by a third party but freely available upon request, please note this and state the owner of the data set and contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data.

c) If the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author).

Please also indicate how any scripts necessary for analysis may be accessed.

3. Throughout: Please include line numbers running throughout the text.

4. Abstract: Please structure your abstract using the PLOS Medicine headings (Background, Methods and Findings, Conclusions).

5. Abstract: Methods and Findings: Please mention the years during which the study took place, when imaging took place relative to baseline assessments, length of follow up for the cognition assessment, and details of main outcome measures.

6. Abstract: Methods and Findings: Please quantify the main results presented with both 95% CIs and p values.

7. Abstract: Methods and Findings: In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology.

8. Abstract: Conclusions: Here, and throughout, please temper assertions such as “This study represents the largest…” with “To the best of our knowledge…” or similar. Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

9. Author summary: At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

10. Introduction: Please avoid vague statements such as “...there are huge public health implications.”

11. Introduction: Please conclude the final paragraph of the Introduction with a clear description of the study’s objectives (in paragraph form, rather than as a numbered list).

12. Methods: Participants: Please clarify if participants with dementia at baseline were excluded. Please provide more detail on how those participants invited for brain/abdominal imaging were selected.

13. Methods: Alcohol consumption: Please clarify that only the current drinkers were categorized into quintiles (excluding former/never drinkers).

14. Methods: Brain imaging: “The fourteen regions correspond to left and right of seven subcortical structures.” Please list the regions, with rationale for why they were selected. Please clarify if data from left/right substantia nigra were available only for QSM (as it seems there were 16 total QSM IDPs).

15. Methods: Genetic variants: For each data source, please describe the study design, size, and the underlying population. Please provide relevant details on selection of the genetic variants. Please consider including a supporting information table to describe sources of data.

16. Methods: Clinical measures: Please clarify in the text which elements of the cognitive battery were assessed at baseline and at follow up. Please clarify the time point of the follow up assessment. Please describe and reference how prospective memory and fluid intelligence were assessed. Please also clarify how the subset of 100,000 participants were invited for the online follow up trail making test assessment.

17. Statistical analyses: Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c) In either case, changes in the analysis-- including those made in response to peer review comments-- should be identified as such in the Methods section of the paper, with rationale.

18. Statistical analyses: Observational: Please clarify how each covariate was assessed, categorized, and incorporated into analyses.

19. Statistical analyses: Observational: Please clarify the numbers of participants with diet/supplement data available, and whether this was missing from other participants, or if this was evaluated in only an invited subset (and how this subset was selected): “For the subset with available data, dietary factors (meat, fish, bread, fruit and vegetable consumption) and dietary iron supplementation were also included as covariates, to test whether differences in diets according to alcohol intake were driving associations.” Please also clarify how diet and supplement data were assessed in participants, and ensure that the results includes the number of participants for which these measures were available in a Table summarizing the characteristics of this sub-sample.

20. Statistical analyses: Observational: Please clarify if participants were excluded based on having an iron chelation prescription: “No included subjects reported iron chelator prescription.”

21. Statistical analyses: Observational: Please clarify how the repeated assessment of TMT (at baseline and follow up) was incorporated into the analysis.

22. Statistical analyses: Causal mediation analysis: Please provide additional detail of the CMA. Please specify, the details of the regression model, the inclusion of variables, confounders, and interaction terms, assumptions, and how missing data were dealt with.

23. Statistical analyses: Mendelian randomization: Please provide complete details for the Mendelian randomization methods used and report the study according to STROBE-MR guidelines. Please mention the three core IV assumptions for the main analysis (relevance, independence and exclusion restriction). Please mention how missing data were dealt with.

24. Statistical analyses: Mendelian randomization: Please comment on risk of bias attributable to participant overlap between the datasets used.

25. Reporting: Please ensure that the observational component of the study is reported according to the STROBE guideline, and include the completed STROBE checklist as Supporting Information. Please ensure that the Mendelian randomization portion of the study is reported according to the STROBE-MR guideline, and include the completed STROBE-MR checklist as Supporting Information.

Please add the following statement, or similar, to the Methods: "This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline, including guidelines specific for Mendelian randomization studies (S1 and S2 Checklist)." or similar.

The STROBE-MR guideline can be found here: https://www.strobe-mr.org/

When completing the checklists, please use section and paragraph numbers, rather than page numbers.

26. Results: Please report the complete results from the study, including the results for each brain region. Currently, results are presented for individual brain regions selectively. PLOS does not permit “data not shown” and request that results for each brain region be provided (at least in the Supporting Information).

27. Results: For all observational analyses, please present the results of both unadjusted and adjusted analyses. Please consistently present both 95% CIs and p values in the text and tables.

28. Results: Associations with brain iron: Please remove the duplicate text here “0.09 standard deviation (S.D.) [95% confidence interval 0.07 to 0.10]), caudate (β=0.06 [0.04 to 0.07]) and substantia nigra (β=0.04 [0.02 to 0.05]), and lower iron in the thalami (β= -0.05 [-0.06 to -0.03” and please report p values for these associations.

29. Results: It is not clear why the results from left putamen are being highlighted. Please provide similar results (e.g. Figure 2A) for all brain regions.

30. Results: “A sensitivity analysis with finer categorisation of alcohol intake confirmed that associations were not observed at lower intakes (SFigure 1).” Please clarify if this means intakes lower than 7 units.

31. Results: “Menopause status did not associate with putamen susceptibility in females, nor did it not alter associations between alcohol and susceptibility (STable 1).” Please clarify if associations by menopause status was investigated for all brain regions.

32. Results: “In the subset with complete data, neither adjustment for dietary factors, including frequency of red meat consumption (SFigure 8), nor dietary iron supplementation (SFigure 9) changed the pattern of associations.” Please provide a comparison of characteristics for those with compared to without these data available (including information on diet and supplementation).

33. Results: Pathways from alcohol to brain iron: Please clarify if the mediation analysis was carried out for each brain region. It is not clear if the example results presented are from the left or right putamen. Please provide the results of the mediation analysis for each brain region in the study in the supporting information files.

34. Results: “Alcohol consumption (>11 units) was associated with higher liver iron measured by MRI, a robust marker of systemic iron stores” Please provide the results supporting this finding, with 95% CIs and p values.

35. Results: “Higher putamen, caudate and hippocampal susceptibility were associated with greater age-related slowing of executive function, and higher putamen and caudate susceptibility with greater age-related differences in fluid intelligence (Figure 6 (A-C) & STable 3).” Age-related slowing seems to imply you are referring to the repeated assessment of the Trail Making Test, while the figures seem to describe cross-sectional associations. Please revise to clarify. Please also clarify why results for putatmen, caudate, and hippocampus are mentioned- and whether findings differed bilaterally (i.e. the choice to include left vs. right in Figure 6).

36. Results: Clinical relevance of elevated brain iron: Please report p values for all results reported, alongside the 95% CIs. Please explain when findings for left vs right hemisphere brain regions are described, whether findings are consistent bilaterally.

37. Discussion: Please present and organize the Discussion as follows: a short, clear summary of the article's findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

38. Discussion: Key findings: Please differentiate between observational evidence, and evidence derived from genetically predicted alcohol use. Please describe as “evidence supporting a causal relationship between AUD and higher serum iron” or similar.

39. References: Please use the "Vancouver" style for reference formatting, and see our website for other reference guidelines https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references:

40. Table 1: Please define units of alcohol in the legend. Please also describe “higher degree” in the legend. In the Methods, please describe how education level was categorized. Please report on all relevant relevant variables incorporated into the analyses.

41. Figure 2: Please include a larger version of Panel A, rather than including this as an inset. Please include p values for Panel A. For the graph, it would be helpful to include more descriptive terms with the axis labels. Please also explain the color code system for the markers.

42. Figure 3: Please also report p values.

43. Figure 5: Please also report p values.

44. Supporting Information: Please make sure that each Supporting Information Figure/Table has a title and a legend.

45. Figures S1 - S9: Please provide p values. Please provide the results of sensitivity analyses for all brain regions included in the study (by octiles of alcohol consumption, with adjustments for diet and iron supplementation).

46. Figure S10: Please move the inset (A) to below the graph, and increase the size. Please include p values with the 95% CIs reported in the panel. The rationale for illustrating findings from right putamen are not clear. Please provide the result for the T2* derived analyses for each brain region in the study, in addition to the right putamen, especially given that the left putamen was selected for illustration in Figure 2.

47. Figure S11: Please include p values and please include the results for each brain region included in the study.

48. Figure S12, S13, S14, S15, S16: Please include p values.

49. Table S1: Please report exact p values, please do not report p<0.05. Please include the data for each brain region in the study.

50. Table S2: It may be helpful to present these data similar to Figure 3 in the main text. Please report exact p values rather than p<0.05.

51. Table S3 and Table S4: Please report exact p values rather than p<0.05, etc. Please present associations for all brain regions included in the study.

Comments from the reviewers:

Reviewer #1: This is an interesting paper testing the somewhat novel hypothesis that alcohol causes cognitive decline via raising iron, using an observational and Mendelian randomization study.

Methods

To clarify the observational study please address the following points

1. Please ensure that the analysis is adjusted comprehensively for confounders. Confounders are typically common causes of exposure and outcome, as explained here. Socio-economic position is often an influential confounder that likely affects many estimates not just those concerning education

2. Please ensure the analysis is not adjusted for consequences of the exposure unless they are independent of the outcome. Adjusting for non-confounders can bias estimates as explained here https://pubmed.ncbi.nlm.nih.gov/16931543/.

3. When assessing interactions, please ensure interactions with confounders are included in the model, as explained here https://pubmed.ncbi.nlm.nih.gov/22422832/

4. Please explain how the issue of the exposure starting before recruitment may affect the estimates as explained here https://pubmed.ncbi.nlm.nih.gov/27237061/

5. Please provide tables showing exposures by potential confounders so that the reader can assess the likely level of confounding

6. Please also provide a table showing how the sample with brain and liver imaging relates to UK Biobank on key characteristics, so that the reader can assess any issues arising from selection

As regards the Mendelian randomization (MR) study, please clarify the following points in the manuscript

1. Were the SNPs used as genetic instruments independent?

2. Were the SNPs used as genetic instruments for iron independent of hepcidin and hereditary hemochromatosis?

3. Did the inverse variance weighted estimates use multiplicative effects?

4. Please include power calculations

5. Would it be possible to use multivariable MR to show that the effect of alcohol on cognition is mediated by iron?

Discussion

To contextualize the results please explain whether any other drivers of iron levels, such as supplements or foods rich in iron, would be expected to, or are known to, have detrimental effects on cognition. Similarly, iron levels vary by sex and population, are corresponding differences in cognition seen?

In the interpretation, please consider whether the changes with age could be a cohort effect. The UK Biobank participants encompass a wide age range recruited over a short time span, so age also represents cohort.

Please give more thorough consideration of the limitations of the methods used.

Reviewer #2: In this new manuscript, Topiwala et al report an association between alcohol consumption and MRI-determined brain iron. This study has public health importance, since the association was observed in even moderate drinkers. The importance of brain iron to neurological diseases is increasingly appreciated, and a proposed model of iron elevation mediating alcohol-related cognitive deficits is plausible. The study examined a large and well characterized dataset (n>22k) of brain MR images, and combined this with additional genetic data, clinical characteristics (including several risk factors), cognitive outcomes, and systemic values of iron from plasma and liver MRI. The authors note a major, but almost unavoidable limitation of this dataset is that alcohol use is self-reported, but otherwise this represents an ideal dataset to perform this study on. This limitation is somewhat mitigated by the use of genetic predictors of alcohol use disorder, where the authors report that these too are associated with brain iron in certain regions. Overall, I found this to be a well conducted, comprehensive, and important study. I have the following comments:

* Age and sex are likely to influence brain iron. I note that the authors controlled for these variables, but it is perhaps likely that the association between alcohol use and brain iron may be non-linear with age, or may be more apparent in either males or females. Is an interaction term of age*alcohol or sex*alcohol significant? Or are there different results when comparing associations in strata of sex or age (young/old). It may be of public health importance to know whether, for example, the association only occurs after a certain age, or only in males.

* The figures were distorted when printed to the PDF. There appear to be random boxes covering parts of the figures, and other significant graphical issues.

* In Figure 2, the colours of the dots are not explained. The inset is hard to read and should be included as a separate table.

* The authors make the case for alcohol use causing brain iron elevation. I think this is likely, but would the authors consider also the reverse possibility - that people with high brain iron are more likely to drink alcohol. A possible mechanism for this is that tyrosine hydroxylase (dopamine-producing enzyme) is dependent on iron.

Scott Ayton

Reviewer #3: The authors use observational and Mendelian randomization (MR) analyses to investigate whether moderate alcohol consumption leads to higher levels of iron concentration in various brain regions, whether this effect of alcohol on brain iron is mediated by systemic iron levels, and whether higher concentration of brain iron causes a sharper decline in age-related cognitive function.

The manuscript uses suitable large-scale datasets, makes use of appropriate methodology, links the obtained results with existing literature and discusses the biological plausibility and clinical relevance of novel findings. I enjoyed reading the manuscript and believe it is already deserving of publication. I have only a few minor comments:

1) The effects of alcohol consumption on health-related traits are sometimes non-linear. At the same time, the authors state that part of their motivation for conducting this study is to consider the impact of moderate alcohol consumption on brain iron levels, as opposed to heavy consumption which has already been investigated in the literature. With that in mind, did the authors observe any evidence of non-linear behaviour in the effects of alcohol consumption on brain iron levels and cognitive function?

2) The authors mention that the genetic variants used in their study explained less than 1% of variation in alcohol consumption. Does that mean their MR analysis could be susceptible to weak instrument bias? Since the paper uses a two-sample design, any such bias would act towards the null, making it harder to identify significant associations between drinking and iron levels. Perhaps it would be a good idea to report F-statistics as an indication of instrument strength in the authors' MR analyses.

3) There must be an issue with the confidence intervals plotted in Figure 6, as the "+1 SD" and "-1 SD" lines seem to be reversed for smaller ages.

4) Directly below Figure 2, a few lines of text have been duplicated - please delete.

Reviewer #4: This is a comprehensive, well-conducted and clearly written examination of the relationship between brain iron and alcohol use. The study includes robust methods and appropriate sensitivity analyses, leading to convincing evidence that low levels of alcohol use are associated with iron accumulation in the brain. Given the prevalence of low-level alcohol use, the findings have considerable public health implications, particularly in terms of improving cognitive health. There are some details we feel should be addressed:

1) The models predicting alcohol use did not include sociodemographic covariates which were included in the models with cognitive outcomes. These covariates seem relevant to the alcohol analyses as well and we wondered why they weren't included? It was also unclear why the models investigating the relationship with serum iron (figures S13 and 14) then included the sociodemographic factors?

2) What was the motivation for including the analysis of genetically predicted AUD? Much of the introduction focuses on moderate levels of alcohol use and the importance of understanding the impact of this from a public health perspective so the inclusion of AUD is surprising. In addition, the statistical analysis section focusing on MR only mentions alcohol consumption not AUD.

3) When describing figures S2-6 the authors state: "Levels of drinking necessary to observe higher susceptibility values differed according to region". It may be worth noting in the text that drinking 7+ units was associated with higher susceptibility for all regions.

4) For sensitivity analyses which stratified the sample by sex and included diet-related covariates, only results for left putamen are shown. This is fine, but please confirm in text that only this is shown for illustrative purposes and that the analyses were conducted for all IDPs and that the pattern of relationships was similar across IDPs (if this is the case). Please also provide n for the sample including diet-related factors.

5) In terms of categorisation of alcohol consumption, the categories overlap slightly (i.e., 7-12, 12-18 etc). Please confirm this is a labelling error and correct if this is the case. The analyses for QSM and T2* seem to have alcohol categorised slightly differently - is there a reason for this?

6) What is the sample size for the serum iron analyses?

7) Can the authors please provide more detail on their causal mediation analysis and how what is presented is different to standard mediation analysis.

8) Given the sample size, one-sample non-linear MR would not have been possible. But given that many studies do find a non-linear relationship between alcohol use and health outcomes (specifically a protective effect of low consumption) consideration of this as a limitation may be included.

Overall, we would like to commend the authors on an impressive piece of work.

Dr Louise Mewton & Ms Rachel Visontay

Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 2

Caitlin Moyer

23 May 2022

Dear Dr. Topiwala,

Thank you very much for re-submitting your manuscript "Impact of moderate alcohol consumption on brain iron and cognition: observational and genetic analyses" (PMEDICINE-D-22-00417R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by four reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by May 30 2022 11:59PM.   

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor 

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

1. Title: We suggest revising to: “Associations between moderate alcohol consumption, brain iron, and cognition in UK Biobank participants: Observational and Mendelian randomization analyses” or similar.

2. Data Availability statement: Your data availability statement currently reads: “Data access on successful UKB data application” in your data availability statement. The Data Availability Statement (DAS) requires revision. We ask that you please note the sources and location, contact information for data access requests, and any relevant DOI or accession number associated with the dataset(s) used in the study.

In the response to editor/reviewer comments letter, you wrote: “Imaging and observational data underlying the results presented are available from the UK

Biobank upon successful application (https://www.ukbiobank.ac.uk/enable-yourresearch/apply-for-access). Genetic summary statistics for serum iron measures are freely available (https://www.decode.com/summarydata/), as are GSCAN summary statistics (https://genome.psych.umn.edu/index.php/GSCAN). Summary statistics for alcohol use disorder are available upon application through dfGaP at accession no. phs0016732.v3.p1 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi study_id=phs001672.v3.p1). Requests for code can be made to the authors.”

Please add this statement to the data availability section of the manuscript submission system.

Regarding the sentence about the access to the analysis code, please note that authors may not serve as the contact points for access requests. All data and related metadata underlying reported findings should be deposited in appropriate public data repositories, unless already provided as part of the submitted article (i.e. as a supporting information file). When possible, we recommend authors deposit restricted data or code to a repository that allows for controlled data access. If this is not possible, directing data requests to a non-author institutional point of contact, such as a data access or ethics committee, helps guarantee long term stability and availability of data. Providing interested researchers with a durable point of contact ensures data will be accessible even if an author changes email addresses, institutions, or becomes unavailable to answer requests.

Please see our policy at http://journals.plos.org/plosmedicine/s/data-availability

3. Abstract: Please combine the Methods and Findings sections into one section, “Methods and findings”.

4. Abstract:Background: Line 95-96: We suggest revising to: “Our objectives were to investigate evidence in support of causal relationships between…”

5. Abstract: Methods and Findings Line 102:: We suggest moving “Observational associations between brain iron markers and self-reported alcohol consumption (n=20,729 UK Biobank participants) were compared with associations with genetically-predicted alcohol intake from two-sample Mendelian randomization (MR).” to the first sentence of the Methods and Findings section. Please indicate the years during which the alcohol consumption data were collected, if different from the study baseline years (2006-2010). Please report the percentage of female participants, and other relevant demographics or inclusion/exclusion criteria.

6. Abstract: Methods and Findings: Line 103-105: Please provide a few words explaining what is represented by each measure (QSM, susceptibility (χ) and T2*) for a non-specialist audience. Please mention the brain regions of interest in the study, at least those for which findings are presented, or mention specific pathways of interest (e.g. subcortical regions involved in motor behavior/learning/cognition, memory, etc).

7. Abstract: Methods and Findings: Please mention how alcohol consumption was evaluated, and please also note that genetically predicted alcohol use disorder was included in the MR anaysis.

8. Abstract: Methods and Findings: Line 111: Please note the measures used to assess cognition, in terms of how the outcomes of executive function, fluid intelligence, reaction time were assessed.

9. Abstract: Methods and Findings: Please provide some summary demographics of the sample, e.g. sex, age, weekly alcohol consumption, proportion of never drinkers.

10. Abstract: Methods and Findings: Please report p values as p<0.001 where applicable.

11. Abstract: Methods and Findings: Please revise to indicate that the MR evidence did not survive correction for multiple testing: “MR analyses provided weak evidence that these relationships are causal. A 1 S.D. higher genetically-predicted number of alcoholic drinks weekly associated with 0.25 S.D. (95% CI:0.01 to 0.49, p=0.04) higher putamen susceptibility and 0.28 S.D. (95% CI:0.05 to 0.50, p=0.02) higher hippocampus susceptibility; however these associations did not survive corrections for multiple testing. Weak evidence for a causal relationship between genetically predicted alcohol use disorder and higher putamen susceptibility was observed (0.18, 95% CI:0.001 to 0.35, p=0.04 S.D.), however, this was not robust to correction for multiple comparisons.” or similar wording.

12. Author Summary: Line 175: We suggest revising to: “These findings suggest that moderate alcohol consumption is associated with higher iron levels in the brain.”

13. Author summary: Line 179: Please provide a few additional words of detail on the limitation of generalizability in your study.

14. Introduction: Line 186: Here and throughout, please remove spaces from reference brackets [1,2].

15. Introduction: Line 216: Please temper with “To the best of our knowledge…” or similar.

16. Introduction: Lines 220 - 228: This description of the various MRI-derived measurements may be more appropriate in the Methods section (e.g. around line 282 “Brain Imaging”).

17. Methods: LIne 252: Please explain how subsets were selected for imaging: “Subsets of these participants (all ancestry) were invited to have brain (n~50,000 analysed to date) and abdominal imaging (n~15,000 analysed to date).”

18. Methods: Line 315: Please also explain how “some participants” came to be invited to undergo liver imaging: “During the same visit that brain imaging was performed, some participants also underwent abdominal imaging…”

19. Methods: Line 331: Genetic variants: Please reference the supporting information file containing information on the 91/92 SNPs for genetically predicted alcohol consumption, and the 24 variants used for the alcohol use disorder analysis.

20. Methods: Line 361: Clinical measures: Please provide additional detail of the outcomes of the trail-making test; prospective memory shape taks, fluid intelligence measures, and motor function tasks (e.g. please include the assessments/questions and any scoring criteria as supporting information documents, or describe in detail in the Methods section).

21. Methods: Line 507: Please reference the website in the reference list. Please refer to the reference guidelines for details: https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references

22. Results: Please report p values as p<0.001 where applicable.

23. Results: Line 566: If relevant, it may be useful to note here that for the finer categorization analysis, the reference category was fewer than 4 units weekly.

24. Results: Line 567-568: Please clarify if this should be: “slightly higher susceptibility in left thalamus…

25. Results: Line 575: Please clarify if this should be: “There were significant interactions with age in bilateral putamen and caudate…

26. Results: Line 580-582: Please clarify this sentence: “Findings with T2* were broadly consistent, although in more limited brain regions (putamen and caudate solely where correlation between T2* and susceptibility higher r= -0.58-0.75).” Please make it clear that this is saying that for T2* associations were only observed in putamen and caudate, and that these are two regions where T2* and susceptibility measures are more highly correlated (if this is accurate).

27. Results: Line 759: The analysis with squared alcohol consumption was not described in the Methods. Please describe this analysis, including the rationale for examining squared consumption with cognitive measures.

28. Discussion: Please check the organization of the Discussion, At Line 877-888: Please make the sections of the Discussion describing strengths and limitations of the study more apparent. We suggest describing the study strengths in one or more paragraphs, followed by a discussion of the limitations in one or more paragraphs.

29. Discussion: Line 934: Please avoid the use of vague statements such as “There are major public health implications…” and instead please provide greater description/discussion of such implications.

30. Discussion: Line 952: We suggest revising to: “Brain iron accumulation is a possible mechanism for alcohol-related cognitive decline.”

31. Line 957: Conflict of Interest: Please remove the conflict of interest statement from the main text. Please be sure all information is entered into the “Competing Interests” section of the manuscript submission system.

32. Line 964: Financial disclosure: Please remove this section from the main text, and please be sure all information is completely and accurately entered into the “Funding” section of the manuscript submission system.

33. Line 996: Data availability: Please remove this section from the main text, and please be sure all information is completely and accurately entered into the “Data availability” section of the manuscript submission system.

34. References: Please check the formatting of each reference. Please use NLM journal title abbreviations. Please update any preprints, where applicable (e.g. Ref 38). Please use the "Vancouver" style for reference formatting, and see our website for other reference guidelines https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references

35. Figures and Tables: Please check each figure/table and ensure that all abbreviations used are defined in each legend, or within the table/figure itself.

36. Figure 2, 3: Please also report the unadjusted associations (this may be in a separate supporting information table). Please report p values as p<0.001 where applicable. Please report p values to 2 decimal places, or 3 decimal places if p<0.01.

37. Figure 5: Please report p values as p<0.001 where applicable. Please report p values to 2 decimal places, or 3 decimal places if p<0.01.

38. S4 Figure, S5 Figure, S6 Figure: Please use “ref” or similar for the <7 units line instead of indicating “0” and please report p values as p<0.001 where applicable.

39. STables: Please also provide a list of Titles/Legends for the two Checklists, and the Supporting Information Tables.

40. S Table 3 and S Table 4: Please provide p values as p<0.001 where applicable. Please report to two decimal places, or 3 decimal places if p<0.01. Please also provide unadjusted associations.

41. S Table 5, S Table 8: Please provide p values as p<0.001 where applicable. Please report to two decimal places, or 3 decimal places if p<0.01.

42. S Table 9: Please provide p values as p<0.001 where applicable. Please report to two decimal places, or 3 decimal places if p<0.01. Please also provide unadjusted associations.

43. S Table 10: Please provide these data for the alcohol use disorder analysis.

Comments from Reviewers:

Reviewer #1: Thank you for this revision I have no further comments

Reviewer #3: I am happy with the authors' response to the comments previously made by me and other reviewers. Therefore, I would like to recommend that their manuscript is accepted for publication.

Reviewer #4: Thank you for attending to our comments. No further comments.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Caitlin Moyer

1 Jun 2022

Dear Dr Topiwala, 

On behalf of my colleagues and the Academic Editor, Perminder Singh Sachdev, I am pleased to inform you that we have agreed to publish your manuscript "Associations between moderate alcohol consumption, brain iron, and cognition in UK Biobank participants: Observational and Mendelian randomization analyses" (PMEDICINE-D-22-00417R3) in PLOS Medicine.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

Please also address the following editorial requests:

-Abstract: Line 126: Please change “found these effects” to “found these associations”

-Abstract: Line 139: Please change to “alcohol use was self-reported”

-Author summary: Line 169: Please change to “cognitive measures associated with higher brain iron” or similar.

-Author summary: Line 177: Please change to “suggest that moderate alcohol consumption is associated with higher iron levels in the brain”

-Table 1: Please add the mean/SD for BMI for the larger UK Biobank sample.

-References: Please check and correct all journal title abbreviations to the appropriate format (e.g. in Ref. 1 bmj should be BMJ).

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Sincerely, 

Caitlin Moyer, Ph.D. 

Associate Editor 

PLOS Medicine

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. STROBE checklist of recommended items to address in cohort studies.

    (DOCX)

    S2 Checklist. STROBE-MR checklist of recommended items to address in reports of mendelian randomization studies.

    (DOCX)

    S1 Fig. Flow chart of participants included in analyses.

    UKB, UK Biobank; QSM, quantitative susceptibility mapping.

    (PNG)

    S2 Fig. Comparison of different 2-sample MR methods for estimating the causal effects of alcohol on brain susceptibility.

    Genetic associations with alcohol consumption were calculated in GWAS and Sequencing Consortium of Alcohol and Nicotine, and genetic associations with susceptibility imaging-derived phenotypes from UKB. Effect estimates for alcohol consumption are per standard deviation increase in genetically predicted log-transformed drinks per week. LCI, lower confidence interval; MR, mendelian randomization; SNP, single nucleotide polymorphisms; UCI, upper confidence interval.

    (PNG)

    S3 Fig. Two-sample MR randomization analyses to estimate the causal effects of alcohol use disorder on brain susceptibility.

    MR estimates (2-sample design) for associations between genetically predicted alcohol use disorder (Million Veterans Program and Psychiatric Genomics Consortium) and susceptibility imaging-derived phenotypes (UK Biobank) in inverse-variance weighted analysis. LCI, lower confidence interval; MR, mendelian randomization; SNP, single nucleotide polymorphism; UCI, upper confidence interval.

    (PNG)

    S4 Fig. Observational associations between weekly alcohol consumption (quintiles) and liver iron (mg/g).

    Reference group is those drinking <7 units (56 g) weekly. Estimates generated from regression models adjusted for: age, educational qualifications, Townsend Deprivation Index, household income, historical job code, smoking, imaging site, diabetes mellitus, BMI, blood pressure, cholesterol, dietary iron, rs1800562, rs1799945, and rs855791. BMI, body mass index; LCI, lower confidence interval; UCI, upper confidence interval.

    (PNG)

    S5 Fig. Observational associations between weekly alcohol consumption (quintiles) and liver protein density fat fraction (%).

    Estimates are adjusted for age, sex, smoking, BMI, cholesterol, blood pressure, diabetes, educational qualifications, Townsend Deprivation Index, household income, and historical job type. BMI, body mass index; LCI, lower confidence interval; UCI, upper confidence interval.

    (PNG)

    S6 Fig. Observational associations between weekly alcohol consumption (quintiles) and liver cT1 (milliseconds), a marker of inflammation/fibrosis.

    Estimates are adjusted for: age, sex, smoking, BMI, cholesterol, blood pressure, diabetes, educational qualifications, Townsend Deprivation Index, household income, and historical job type. All estimates are within the normal reference range [88]. BMI, body mass index; LCI, lower confidence interval; UCI, upper confidence interval.

    (PNG)

    S7 Fig. Comparison of different two-sample MR estimates of the causal effect of alcohol used disorder on serum markers of iron homeostasis.

    Genetic associations of alcohol use disorder generated in the Million Veterans Program and Psychiatric Genomics Consortium and of serum markers of iron homeostasis from deCODE, INTERVAL, and the Danish Blood Donor Study. LCI, lower confidence interval; MR, mendelian randomization; SNP, single nucleotide polymorphism; TIBC, total iron binding capacity; UCI, upper confidence interval.

    (PNG)

    S8 Fig. Two-sample MR estimates of the causal effects of alcohol consumption and alcohol use disorder on serum iron markers.

    Genetically predicted alcohol consumption was log-transformed drinks per week, generated from GWAS and Sequencing Consortium of Alcohol and Nicotine. Genetic associations with alcohol use disorder were generated from the Million Veterans Program and Psychiatric Genomics Consortium. Genetic associations with serum iron markers were calculated in cohorts that did not adjust for alcohol in their genome-wide association study (DECODE unless otherwise marked). LCI, lower confidence interval; SNP, single nucleotide polymorphism; UCI, upper confidence interval.

    (PNG)

    S1 Table. Summary statistics sources for genetic associations with alcohol intake, alcohol use disorder, serum iron measures, and brain iron measures.

    (XLSX)

    S2 Table. Baseline characteristics according to alcohol intake.

    (XLSX)

    S3 Table. Observational associations between alcohol consumption and brain iron measures.

    (XLSX)

    S4 Table. Unadjusted observational associations between weekly alcohol intake (quintiles) and brain susceptibility.

    (XLSX)

    S5 Table. Observational associations between weekly alcohol intake (octiles) and brain susceptibility.

    (XLSX)

    S6 Table. Observational associations between (1) alcohol intake and brain susceptibility controlling for menopause status; and (2) susceptibility and menopause status.

    (XLSX)

    S7 Table. Baseline characteristics for sample with diet and iron supplementation data.

    (XLSX)

    S8 Table. Observational associations between weekly alcohol intake (quintiles) and brain susceptibility, additionally adjusted for diet and iron supplementation.

    (XLSX)

    S9 Table. Mediation analyses for all brain regions.

    (XLSX)

    S10 Table. Observational associations between brain susceptibility and cognitive test performance at time of the scan.

    (XLSX)

    S11 Table. F statistics for genetic instruments for alcohol consumption.

    (XLSX)

    Attachment

    Submitted filename: Plos Medicine rebuttal 7.4.22.docx

    Data Availability Statement

    Imaging and observational data underlying the results presented are available from the UK Biobank upon successful application (https://www.ukbiobank.ac.uk/enable-yourresearch/apply-for-access). Genetic summary statistics for serum iron measures are freely available (https://www.decode.com/summarydata/), as are GSCAN summary statistics (https://genome.psych.umn.edu/index.php/GSCAN). Summary statistics for alcohol use disorder are available upon application through dfGaP at accession no. phs0016732.v3.p1 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi study_id=phs001672.v3.p1).


    Articles from PLoS Medicine are provided here courtesy of PLOS

    RESOURCES